Cyclic dinucleotides as agonists of interferon gene stimulatory factor-dependent signal transduction.

Novel cyclic dinucleotide compounds modulate STING activity to induce balanced immune responses, serving as effective adjuvants in vaccines for disease prevention and treatment, particularly cancer.

JP7591348B2Active Publication Date: 2024-11-28BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2019544894
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-02-21
Filing Date
2018-02-21
Publication Date
2024-11-28
Estimated Expiration
2038-02-21

AI Technical Summary

Technical Problem

There is a need for new compounds that can act as adjuvants for vaccines to induce a strong immune response involving both humoral and cellular components, effectively preventing or treating a wide range of diseases, particularly cancer, while being non-toxic to humans.

Method used

Development of novel cyclic dinucleotide compounds with specific structural formulas that modulate STING activity, capable of inducing or enhancing immune responses and serving as adjuvants in vaccines.

Benefits of technology

These compounds effectively stimulate both humoral and cellular immune responses, providing balanced immune reactions for disease treatment and prevention, including cancer, without toxicity to humans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591348000001
    Figure 0007591348000001
  • Figure 0007591348000002
    Figure 0007591348000002
  • Figure 0007591348000003
    Figure 0007591348000003
Patent Text Reader

Abstract

Disclosed herein are novel cyclic dinucleotide compounds and compositions and their applications as pharmaceutical agents for the treatment of disease. Also provided are methods for modulating immune responses to disease and for inducing stimulator of interferon genes (STING)-dependent type I interferon production and co-regulatory genes in human or animal subjects for use in the treatment of diseases such as cancer, particularly metastatic solid tumors and lymphoma, inflammation, allergic and autoimmune diseases, infectious diseases, and as antiviral agents and vaccine adjuvants.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 461,642, filed February 21, 2017, the contents of which are incorporated by reference herein as if set forth in their entirety. [Background technology]

[0002] Disclosed herein are novel cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease, as well as methods for modulating immune responses to disease to induce stimulator of interferon genes (STING)-dependent type I interferon production and co-regulated genes. Methods for modulating STING activity in a human or animal subject are also provided for the treatment of diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune diseases, infectious diseases, and for use as vaccine adjuvants.

[0003] Invertebrates are constantly threatened by microbial invasion and have evolved immune defense mechanisms to eliminate infectious pathogens. In mammals, this immune system includes two branches: innate immunity and adaptive immunity. The innate immune system is the first line of defense initiated by pattern recognition receptors (PRRs) that detect ligands from pathogens as well as damage-associated molecular patterns (Tokeuchi, O. et al., Cell 2010, 140, 805-820). An increasing number of these receptors have been identified, including Toll-like receptors (TLRs), C-type lectin receptors, retinoic acid-inducible gene I (RIG-1)-like receptors and NOD-like receptors (NLRs) as well as double-stranded DNA sensors. Activation of PRRs results in the upregulation of genes involved in the immune response. This response utilizes factors such as type 1 interferons, inflammatory cytokines and chemokines that suppress pathogen replication as well as promote adaptive immunity.

[0004] The adaptor protein STING (Stimulator of Interferon Genes), also known as TMEM 173, MPYS, MITA and ERIS, has been identified as a central signaling molecule in the innate immune response to cytosolic nucleic acids (Ishikawa, H.; Barber, GN Nature 2008, 455, 674-678; WO 2013 / 1666000). Activation of STING leads to upregulation of IRF3 and NFKB pathways, which leads to induction of interferon-β and other cytokines. STING is important for responses to cytosolic DNA from pathogens or hosts, as well as specific nucleic acids called cyclic dinucleotides (CDNs). Initially characterized as ubiquitous bacterial second messengers, CDNs [cyclic di-GMP (guanosine 5'-monophosphate) (CDG), cyclic di-AMP (adenosine 5'-monophosphate) (CDA), and cyclic GMP-AMP (cGAMP)] constitute a class of pathogen-associated molecular pattern molecules (PAMPs) that activate the TBK1 / interferon regulatory factor 3 (IRF3) / type 1 interferon (IFN) signaling axis via the cytoplasmic pattern recognition receptor Stimulator of Interferon Genes (STING). Bacterial CDNs, such as CDG, are symmetric molecules characterized by two 3',5' phosphodiester bonds.

[0005] Direct activation of STING by cellular CDNs was recently confirmed by X-ray crystallography (Burdette, DL; Vance, RE Nature Immunology 2013, 14, 19-26; Cai, X. et al. Molecular Cell 2014, 54, 289-296). More recently, a response to cytosolic DNA was elucidated that involves the production of a novel mammalian CDN signaling molecule, identified as cGAMP, by an enzyme called cyclic GMP-AMP synthase (cGAS, formerly C6orf150 or MB21D1), which in turn activates STING. Unlike bacterial CDNs, cGAMP is an asymmetric molecule characterized by its mixed 2',5' and 3',5' phosphodiester bonds. (Gao, P. et al. Cell 2013, 153, 1-14).

[0006] Interferons were first described as substances capable of protecting cells against viral infection (Isaacs, A.; Lindemann, J. Proc. Royal Soc. Lon. Ser. B. Biol. Sci. 1957, 147, 258-267). Interferons belong to a class of small proteins known as cytokines, which are involved in intercellular signaling. In humans, type I interferons are a family of related proteins encoded by a gene on chromosome 9 that codes for at least 13 isoforms of interferon alpha (IFNα) and one isoform of interferon beta (IFNβ). Recombinant IFNα was the first approved biotherapeutic drug and has become an important treatment in viral infections and cancer. As well as direct antiviral activity on cells, interferons have been found to be potent agonists of the immune response acting on cells of the immune system.

[0007] The administration of small molecule compounds capable of stimulating the innate immune response, including activation of type I interferon and other cytokines, may be an important strategy for the treatment or prevention of human diseases, including viral infections. Compounds capable of stimulating the immune response are useful not only in infectious diseases, but also in cancer (Krieg, Curr. Oncol. Rep. 2004, 6(2), 88-95), allergic diseases (Moisan J. et al. Am. J. Physiol. Lung Cell Mol. Physiol. 2006, 290, 1987-1995), other inflammatory diseases such as irritable bowel disease (Rakoff-Nahoum, S. et al. Cell 2004, 23, 118(2), 229-241), and as vaccine adjuvants (Persing, DH et al. Trends Microbiol. 2002, 10(10 Suppl), S32-S37).

[0008] Induction of type 1 interferon by activation of STING may benefit the treatment of allergic diseases such as asthma and allergic rhinitis (Huber, JP et al. J. Immunol. 2010, 185, 813-817). Recent evidence has accumulated to suggest that allergen-reactive type 2 helper T cells (Th2) play a role in triggering the activation and / or recruitment of IgE antibody-producing B cells, mast cells and eosinophils, all of which are involved in allergic inflammation. Th2 responses are associated with increased levels of IgE, which, through its action on mast cells, promotes hypersensitivity to allergens, resulting in the symptoms seen, for example, in allergic rhinitis and asthma. In healthy individuals, the immune response to allergens is more balanced with a mixed Th2 / Th1 and regulatory T cell response. Induction of type 1 interferon has been shown to cause a reduction in Th-type cytokines in the local environment and promotes Th1 / Treg responses.

[0009] Activation of the stimulator of interferon genes (STING) pathway has been identified as one of the key determinants in the generation of spontaneous T cell responses in vivo. The STING pathway is activated by tumor-derived DNA in the cytosol of dendritic cells (DCs), which in turn leads to increased levels of cGAMP. Antigen-presenting cells (APCs) such as DCs are involved in the antitumor T cell response pathway. Upon exposure to immune danger signals, DCs act as potent T cell stimulators through the induction of cGAS, followed by the production of cGAMP, which then binds to STING. This pathway induces phenotypic maturation of DCs, followed by the production of type I interferons and other cytokines. Activation of STING induces the transcription of numerous host defense genes, resulting in the production of interferon beta, chemokine release, and finally the priming of antigen-specific T cells, thus triggering spontaneous antitumor T cell responses. Innate immune activation by STING agonists in the tumor microenvironment leads to vascular rupture and rapid tumor destruction, followed by T cell-mediated adaptive immunity against residual disease. Pharmacological stimulation of the STING pathway with chemically modified cyclic dinucleotides has proven therapeutically effective presymptomatically against tumors in relevant in vivo models and offers great promise in the clinical setting, with the first STING agonists currently in Phase I trials in patients with metastatic solid tumors or lymphomas. Intratumoral injection of an optimized STING agonist is currently in clinical trials in Phase I trials in patients with advanced cancer (NCT02675439).

[0010] Induction of IFN in Listeria-infected cells is STING-dependent and abolished in goldenticket mice carrying a mutant STING allele. Other observations, including CDG-STING co-crystal structures, have revealed that cytosolic microbial CDNs bind STING to trigger IFN and inflammatory signaling cascades. The STING signaling pathway has emerged as a central TLR-independent mediator of host innate defense stimulated by cytosolic nucleic acids, either through direct binding of exogenous CDNs from bacteria or binding of structurally distinct CDNs produced by host cGAS in response to cytosolic double-stranded DNA (dsDNA). The STING pathway represents a central lymph node-bound cytosolic nucleic acid for transcriptional responses, resulting in MyD88-independent production of type I IFNs.

[0011] Modulation of STING is promising for the development of compounds with antiviral activity. Pathogen recognition is primarily mediated by PRRs, including TLRs, RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs) (Takeuchi, O. et al. Cell 2010, 140, 805-820), which trigger signal cascades to upregulate the expression of various cytokines. In the case of viral infection, endosomal TLRs and cytoplasmic RLRs detect viral DNA or RNA and induce the production of type I IFNs, which are potent inhibitors of viral replication (Gitlin, L. et al. PNAS USA 2006, 103, 8459-8464; Kato, H. et al. Nature Immunol. 2005, 23, 19-28; Kato, H. et al. Nature 2006, 441, 101-105). STING has been shown to activate downstream transcription factors STAT6 and IRF3 through TBK1, which are responsible for antiviral responses and innate immune responses against intracellular pathogens. Recently, it has been reported that in response to viral infection, STING activates STAT6 (signal transducer and activator of transcription 6) to induce (Th2 type), increase (IL-2) or decrease (IL-10) the production of various cytokines, including the chemokines CCL2, CCL20, and CCL26 (Chen, H. et al. Cell 2011, 147, 436-446).

[0012] Compounds and pharmaceutical compositions, some of which have been found to modulate STING activity, are found along with methods of synthesizing and using the compounds, including methods of treating STING-mediated diseases in patients by administering the compounds.

[0013] The present invention also relates to novel adjuvants and their use in pharmaceutical compositions such as vaccines. In particular, the present invention provides novel compounds useful as adjuvants and / or immunomodulators for prophylactic and / or therapeutic vaccines in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies, and for managing fertility in human or animal populations.

[0014] Vaccination has become the most cost-effective means of preventing infection. However, there are still many diseases for which vaccines are not yet available or for which the available vaccines are not completely satisfactory due to low efficacy, high reactogenicity, instability and / or high cost. Therefore, new and improved vaccines are still urgently needed.

[0015] Recent findings suggest that vaccines may also be used for the immunotherapy of infectious diseases. In addition, vaccines may also be used for the prevention or immunotherapy of autoimmune diseases, inflammatory diseases, tumors, allergies, and for the management of fertility in human and / or animal populations.

[0016] The use of optimal adjuvants plays an important role in vaccination. Antigens administered without adjuvants rarely mediate an appropriate immune response. In addition, not only the strength but also the quality of the induced immune response is important. Stimulation of inappropriate immune patterns can cause immunopathological reactions and exacerbation of infectious disease symptoms. In this context, adjuvants can help promote a desired immune response. In other words, adjuvants can modulate or redirect the immune response to balance the immune response in a desired direction.

[0017] Substances called "adjuvants" are those that are added and / or co-formulated with immunization against the actual antigen (i.e., the substance that induces the desired immune response) in order to enhance the humoral and / or cellular immune response ("Lexikon der Biochemie und Molekularbiologie", 1. Band, Spektrum, Akademischer Verlag 1995). That is, adjuvants are compounds that have immune-enhancing properties, especially when co-administered with an antigen. The use of many adjuvants is based only on experience, and the effects cannot be precisely described or predicted. Among others, the following groups of adjuvants are traditionally used: aluminum hydroxide, emulsions of mineral oil, saponins, detergents, silicon compounds, thiourea, endotoxins of gram-negative bacteria, endotoxins of gram-positive bacteria, killed or attenuated live bacteria or parts thereof.

[0018] Potentially useful adjuvants for mucosal vaccination include the following: MALP-2 molecule and its bisacyloxypropylcysteine-conjugates, such as bispalmitoyloxypropylcysteine-PEG molecules, have been shown to be potent stimulators of macrophages. The usefulness of MALP-2 as an adjuvant has been previously demonstrated, see, for example, WO 2004 / 009125 and WO 2003 / 084568. In particular, it has been demonstrated that MALP-2 can act as an effective mucosal adjuvant to enhance mucosal immune responses, for example promoting increased expression of antigen-specific IgA antibodies.

[0019] Moreover, MALP-2 can activate dendritic cells and B cells, both of which have been shown to play important roles in the induction of specific humoral immune responses.In addition, preliminary studies have demonstrated that the combination of biologically active HIV-1 tat protein and synthetic MALP-2 may be a promising vaccine containing MALP-2 components as an effective mucosal adjuvant.

[0020] Intensive research has been carried out in recent years into new adjuvants, including those for mucosal routes of administration. Only a few substances have been found capable of enhancing mucosal responses. Of these, some act as carriers to which the antigen must be bound or fused. As outlined above, much fewer "true" adjuvants have been found that can be mixed with antigens and used universally.

[0021] Like eukaryotic cells, prokaryotic cells also use various small molecules for cell signaling and intracellular and intercellular communication. For example, cyclic nucleotides such as cGMP and cAMP have been found to have regulatory and initiation activities in prokaryotic and eukaryotic cells. In the case of eukaryotic cells, cAMP and cGMP are used as signaling molecules, while prokaryotic cells use cyclic dinucleoside monophosphate molecules, especially CDG, in addition to cAMP.

[0022] Condensation of two GTP molecules is catalyzed by the enzyme diguanylate cyclase (DGC) to give CDG, which has demonstrated antimicrobial activity and can be used to prevent or combat pathogens. Furthermore, CDG acts as an important bacterial regulator: in bacterial cells, CDG regulates the expression of genes and the biosynthesis of exopolysaccharides. Moreover, CDG is not involved in eukaryotic biochemical pathways. As the interacting ligands of CDG are expressed throughout diverse bacterial genera, it is assumed that most bacteria use CDG as a regulatory molecule.

[0023] Therefore, bacterial CDNs and their analogs have attracted interest as potential vaccine adjuvants (Libanova R. et al. Microbial Biotechnology 2012,5,168-176; WO 2007 / 054279, WO 2005 / 087238). WO 2005 / 087238 speculates that CDG or its analogs may stimulate or enhance the immune or inflammatory response of patients, or may enhance the immune response to vaccines by acting as an adjuvant. It also speculates that CDG or its analogs may be used as an active ingredient in compositions for treating injuries, diseases, disorders and conditions that cause neurodegeneration. Therein, data is provided showing that cyclic di-GMP does not regulate DC intracellular activity, but may activate dendritic cells by inducing the expression of costimulatory molecules. Furthermore, data is provided showing that CDG may sometimes upregulate the immune stimulatory capacity of dendritic cells. Furthermore, data are provided showing that high doses of CDG can activate T cells in vitro when mixed with dendritic cells. However, no enhancement of immune or inflammatory responses in patients or enhancement of immune responses to vaccines by acting as an adjuvant is shown, and instead, some data are speculated therein that may show increased antigen presentation by stimulating HLA-DR. Furthermore, no immunomodulatory effect of cyclic di-GMP is shown in the document. Thus, the document merely speculates on some immunomodulatory response, in particular some enhanced immune response, by acting as an adjuvant. As already mentioned, an adjuvant is a compound capable of eliciting or enhancing a humoral and / or cellular immune response against an active antigen. WO2005 / 087238 does not provide data showing an immune response against an active antigen using CDG as an adjuvant to enhance or elicit or modulate said immune response. In addition, it is noted that the document only provides information on CDG and nothing on other analogues of cyclic di-GMP.

[0024] The discovery of the STING pathway and the CDNs that activate it has opened up several new possibilities for the development of vaccine adjuvants. STING agonists could be candidates for clinical trials as adjuvants and as stimulators of anti-cancer immune activity. DMXAA, which significantly shrinks cancer in mouse models by activating the innate immune response, is a STING agonist that activates mouse STING (mSTING) but not hSTING. To validate the therapeutic hypothesis that STING agonists are effective in treating cancer or as vaccine adjuvants, molecules active in humans will be required. Analogs of cGAMP that are resistant to its activity have been validated for use as vaccine adjuvants (Li, L. et al. Nature Chem. Biol. 2014, 10, 1043-1048). Summary of the Invention [Problem to be solved by the invention]

[0025] There is a need to provide novel compounds useful as adjuvants for use with vaccines. In particular, there is a need for adjuvants that are capable of eliciting a strong immune response that exhibits a balanced or regulated immune response, including both humoral and cellular components, thereby allowing for the effective prevention or treatment of a wide variety of diseases and conditions, particularly infectious diseases or cancer.

[0026] It is therefore an object of the present invention to provide adjuvants that can induce, enhance or modulate the (existing) immune response of an individual or subject. In particular, the present disclosure relates to the development of a variety of novel, highly active adjuvants, in particular, mucosal adjuvants, that are non-toxic to humans and can be used with a wide variety of active ingredients that one wishes to promote in conventional or novel vaccines, such as, for example, prophylactic or therapeutic vaccines, including, in particular, cancer and DNA vaccines. [Means for solving the problem]

[0027] In certain embodiments of the invention, the compound has the structural formula Ia: [ka] (In the formula, A1 and A2 are independently selected from CH and N; R 1a and R 1b is independently selected from H and NH2; R2 is selected from OH, F, Cl, N3, and NH2; R3 is selected from OH, F, Cl, N3, and NH2; R 4a and R 4b is independently selected from NH2, OH, NHR5, and OR5; R5 is independently selected from methyl, ethyl, and propyl; However, here, When A1 is CH, R 4a is not NHR5 or OR5; When A2 is CH, R 4b is not NHR5 or OR5; When A1 and A2 are both N, at least one of R2 and R3 is not OH. or a salt, ester, tautomer, or prodrug thereof.

[0028] Additionally, all stereoisomers (including enantiomers and diastereomers) of the compounds of formula Ia are provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] In certain embodiments of the invention, the compound has structural formula I: [ka] (In the formula, A1 and A2 are independently selected from CH and N; R 1a and R 1b is independently selected from H and NH2; R2 is selected from OH, F, Cl, N3, and NH2; R3 is selected from OH, F, Cl, N3, and NH2; R 4a and R 4b is independently selected from NH2, OH, NHR5, and OR5; R5 is independently selected from methyl, ethyl, and propyl; However, here, When A1 is CH, R 4a is not NHR5 or OR5; When A2 is CH, R 4b is not NHR5 or OR5; When A1 and A2 are both N, at least one of R2 and R3 is not OH. or a salt, ester, tautomer, or prodrug thereof.

[0030] Certain compounds disclosed herein may be considered to have useful STING-modulating activity and may therefore be used to treat or prevent diseases or conditions in which STING plays an active role. Thus, in a broad aspect, certain embodiments provide pharmaceutical compositions comprising one or more compounds disclosed herein together with a pharma-ceutically acceptable carrier, as well as methods of making and using these compounds and compositions. Certain embodiments provide methods of modulating STING. Other embodiments provide methods of treating STING-mediated disorders in patients in need of such treatment, comprising administering to said patient a therapeutically effective amount of a compound or composition of the invention. Also provided is the use of certain compounds disclosed herein for use in the manufacture of a medicament for treating a disease or condition ameliorated by receptor activation of STING.

[0031] Those skilled in the art of chemistry will understand that the compound of formula (Ia) has several asymmetric tetrahedral atoms. Formula (Ia) encompasses compounds with all possible absolute stereochemical combinations at various asymmetric tetrahedral atoms. Due to the non-identical substitutions at the two tetrahedral phosphorus atoms, each atom becomes a chiral center. Formula (Ia) encompasses compounds with all possible absolute stereochemical combinations at the two asymmetric tetrahedral phosphorus atoms.

[0032] In certain embodiments of the invention, the compound has the structural formula IIa: [ka] (In the formula, A1 and A2 are independently selected from CH and N; R 1a and R 1b is independently selected from H and NH2; R2 is selected from OH, F, and Cl; R3 is OH; R 4a and R 4b is independently selected from NH2 and OH; When A1 and A2 are both N, R2 is not OH. or a salt, ester, tautomer, or prodrug thereof.

[0033] Also provided are stereoisomers of formula IIa, including enantiomers and diastereomers where the phosphorus shown in formula IIa has R absolute stereochemistry.

[0034] In certain embodiments of the invention, the compound has structural formula II: [ka] (In the formula, A1 and A2 are independently selected from CH and N; R 1a and R 1b is independently selected from H and NH2; R2 is selected from OH, F, and Cl; R3 is OH; R 4a and R 4b is independently selected from NH2 and OH; When A1 and A2 are both N, R2 is not OH. or a salt, ester, tautomer, or prodrug thereof.

[0035] In certain embodiments of any of formulas I, Ia, 2, and 2a, A 1 is CH and A 2 is N.

[0036] In certain embodiments of any of formulas I, Ia, 2, and 2a, A1 is N and A2 is CH.

[0037] In certain embodiments of any of formulas I, Ia, 2, and 2a, A1 and A2 are both CH.

[0038] In certain embodiments of any of formulas I, Ia, 2, and 2a, A 1 and A 2 are both N.

[0039] In certain embodiments of any of Formulas I, Ia, 2, and 2a, A1 and A2 are both N and R2 is selected from F and Cl.

[0040] In certain embodiments of any of Formulas I, Ia, 2, and 2a, R 1a and R 1b Both are H.

[0041] In certain embodiments of any of Formulas I, Ia, 2, and 2a, R 4a and R 4b is independently selected from NH2 and NHR5.

[0042] In certain embodiments of any of Formulas I, Ia, 2, and 2a, R 4a and R 4b is independently selected from NH2 and NHR5, and R 1aand R 1b Both are H.

[0043] In certain embodiments of any of Formulas I, Ia, 2, and 2a, R 4a and R 4b Both are NH2.

[0044] In certain embodiments of any of Formulas I, Ia, 2, and 2a, R 4a and R 4b are both NH2 and R 1a and R 1b Both are H.

[0045] Further, the species described herein, such as: [ka] [ka] Also provided is a compound selected from:

[0046] In certain embodiments, the compound is: [ka] or a salt, ester, tautomer, or prodrug thereof.

[0047] In certain embodiments, the compound is: [ka] or a salt, ester, tautomer, or prodrug thereof.

[0048] In certain embodiments, the compound is: [ka] or a salt, ester, tautomer, or prodrug thereof.

[0049] In certain embodiments, the compound is: [ka] or a salt, ester, tautomer, or prodrug thereof.

[0050] In certain embodiments, the compound is: [ka] or a salt, ester, tautomer, or prodrug thereof.

[0051] In certain embodiments, the compound is: [ka] or a salt, ester, tautomer, or prodrug thereof.

[0052] In certain embodiments, the compound is: [ka] or a salt, ester, tautomer, or prodrug thereof.

[0053] Also provided is a compound selected from the examples disclosed herein, or a salt, ester, tautomer, or prodrug thereof.

[0054] Additionally, embodiments are provided in which the compounds of Formula Ia are conjugated to a targeting moiety for targeted delivery.

[0055] In certain embodiments, the targeting moiety is biotin or a biotin analogue.

[0056] In certain embodiments, the targeting moiety is a peptide.

[0057] In certain embodiments, the targeting moiety is a protein.

[0058] In certain embodiments, the protein is transferrin.

[0059] In certain embodiments, the targeting moiety is an antibody.

[0060] Additionally, embodiments are provided in which the compounds of Formula Ia are conjugated to an antibody for targeted delivery.

[0061] In certain embodiments, the antibody is a monoclonal antibody.

[0062] Additionally, embodiments are provided in which the compounds of Formula Ia are conjugated to a hapten for binding to an antibody for targeted delivery.

[0063] Additionally, embodiments are provided in which the compounds of formula Ia are conjugated to nanoparticles for targeted delivery.

[0064] In certain embodiments, the nanoparticles are composed of polymers of one or more alpha-hydroxycarboxylic acids.

[0065] Also provided are embodiments in which the compound of formula Ia is contained within a polymeric delivery vehicle.

[0066] Additionally, embodiments are provided in which the compound of formula Ia is contained within a liposome.

[0067] Additionally, embodiments are provided in which the compound of formula Ia is contained within a micelle.

[0068] Additionally, there is provided an embodiment in which the compound of formula Ia is contained within a vesicle.

[0069] In certain embodiments, the vesicles are composed of phospholipids.

[0070] Also provided are embodiments in which any of the above embodiments may be combined with any one or more of these embodiments, however the combinations are not intended to be mutually exclusive.

[0071] As used herein, two embodiments are "mutually exclusive" when one is defined as being different from the other. For example, an embodiment in which two groups are bonded to form a cycloalkyl is mutually exclusive from an embodiment in which one group is ethyl and the other group is hydrogen. Similarly, an embodiment in which one group is CH2 is mutually exclusive from an embodiment in which the same group is NH.

[0072] The present invention also relates to a method of inhibiting at least one STING function, comprising contacting STING with a compound described herein. The cell phenotype, cell proliferation, activity of STING, changes in biochemical output produced by active STING, expression of STING, or binding of STING to a natural binding partner can be monitored. Such a method can be a disease treatment modality, a biological assay, a cellular assay, a biochemical assay, etc.

[0073] Also provided herein is a method for treating a STING-mediated disease, comprising administering a therapeutically effective amount of a compound disclosed herein, or a salt thereof, to a patient in need thereof.

[0074] In certain embodiments, the STING-mediated disease is an autoimmune disease or disorder.

[0075] In certain embodiments, the STING-mediated disease is an immune deficiency or deficiency.

[0076] In certain embodiments, the STING-mediated disease is an immune disease or disorder.

[0077] In certain embodiments, the STING-mediated disease is cancer.

[0078] In certain embodiments, the cancer is selected from metastatic solid tumors and lymphoma.Also provided herein are the compounds disclosed herein for use as a medicament.

[0079] Also provided herein are compounds disclosed herein for use as an agent for the treatment of a STING-mediated disease.

[0080] Also provided is the use of the compounds disclosed herein as a medicine.

[0081] Also provided is the use of the compounds disclosed herein as agents for the treatment of STING-mediated diseases.

[0082] Also provided is a compound disclosed herein for use in the manufacture of a medicament for the treatment of a STING-mediated disease.

[0083] Also provided is the use of the compounds disclosed herein for the treatment of a STING-mediated disease.

[0084] Also provided herein is a method for activating a STING receptor, comprising the step of contacting STING with a compound disclosed herein or a salt thereof.

[0085] Also provided herein is a method for achieving an effect in a patient, comprising administering to the patient a therapeutically effective amount of a compound disclosed herein or a salt thereof, the effect being selected from induction of transcription of host defense genes, production of interferon-beta, release of chemokines, and priming of antigen-specific T cells.

[0086] In certain embodiments, the STING-mediated disease is an autoimmune disease or disorder.

[0087] In certain embodiments, the STING-mediated disease is an immune deficiency or deficiency.

[0088] In certain embodiments, the STING-mediated disease is an inflammatory disease.

[0089] In certain embodiments, the STING-mediated disease is cancer.

[0090] In certain embodiments, the cancer is selected from a metastatic solid tumor and a lymphoma.

[0091] Also provided are methods of modulating STING-mediated function in a subject, comprising administering a therapeutically effective amount of a compound disclosed herein.

[0092] Also provided are pharmaceutical compositions comprising a compound disclosed herein in association with a pharma- ceutically acceptable carrier.

[0093] In certain embodiments, the pharmaceutical composition is formulated for oral administration.

[0094] In certain embodiments, the oral pharmaceutical composition is selected from a tablet and a capsule.

[0095] In certain embodiments, the pharmaceutical composition is formulated for parenteral administration, which in certain embodiments is selected from subcutaneous, intravenous, intramuscular, intraarterial, intradermal, intrathecal, and epidural.

[0096] In certain embodiments, the pharmaceutical composition is formulated for intratumoral administration.

[0097] term As used herein, the following terms have the indicated meanings.

[0098] When a range of values ​​is disclosed and the notation "n1··· to n2" or "between n1··· and n2" (where n1 and n2 are numbers) is used, the notation is intended to include the numbers themselves and the range between these numbers, unless otherwise specified. The range may be integer or continuous between the end values, and is inclusive of the end values. As an example, the range "2 to 6 carbons" is intended to include 2, 3, 4, 5, and 6 carbons, since carbon is an integer unit. Compare, as an example, the range "1 to 3 μM (micromolar)", which is intended to include 1 μM, 3 μM, and all significant digits of any number therebetween (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).

[0099] The term "about" as used herein is intended to indicate that the numerical value it modifies represents such value as a variable within a margin of error. In the absence of a specific margin of error, such as a standard deviation for an average value given in a chart or table of data, the term "about" should be understood to mean a range that may encompass the stated value, and also a range that may be encompassed by rounding up or down to that number, taking into account significant digits.

[0100] The term "acyl" as used herein, alone or in combination, refers to a carbonyl bonded to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety, where the atom bonded to the carbonyl is carbon. An "acetyl" group refers to a -C(O)CH3 group. An "alkylcarbonyl" or "alkanoyl" group refers to an alkyl group bonded to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl, and aroyl.

[0101] The term "alkenyl" as used herein, alone or in combination, refers to a straight or branched chain hydrocarbon radical having one or more double bonds and containing 2 to 20 carbon atoms. In certain embodiments, said alkenyl may contain 2 to 6 carbon atoms. The term "alkenylene" refers to a carbon-carbon double bond system bonded at two or more positions, such as ethenylene [(-CH=CH-), (-C::C-)]. Examples of suitable alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl, and the like. Unless otherwise specified, the term "alkenyl" may include an "alkenylene" group.

[0102] The term "alkoxy," as used herein, alone or in combination, refers to an alkyl ether radical, where the term alkyl is as defined below. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.

[0103] The term "alkyl," as used herein, alone or in combination, refers to a straight or branched chain alkyl radical containing 1 to 20 carbon atoms. In certain embodiments, the alkyl may contain 1 to 10 carbon atoms. In further embodiments, the alkyl may contain 1 to 8 carbon atoms. The alkyl group may be optionally substituted as defined below. Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl, and the like. The term "alkylene," as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon bonded at two or more positions, such as methylene (-CH2-). Unless otherwise specified, the term "alkyl" may include an "alkylene" group.

[0104] The term "alkylamino," as used herein, alone or in combination, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups can be mono- or dialkylated forming groups, such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino, and the like.

[0105] The term "alkylidene," as used herein, alone or in combination, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.

[0106] The term "alkylthio" as used herein, alone or in combination, refers to an alkylthioether (RS-) radical, where the term alkyl is as defined above and the sulfur may be singly or doubly oxidized. Examples of suitable alkylthioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.

[0107] The term "alkynyl" as used herein, alone or in combination, refers to a straight or branched chain hydrocarbon radical having one or more triple bonds and containing 2 to 20 carbon atoms. In certain embodiments, said alkynyl contains 2 to 6 carbon atoms. In further embodiments, said alkynyl contains 2 to 4 carbon atoms. The term "alkynylene" refers to a carbon-carbon triple bond attached at two positions, such as ethynylene (-C:::C-, -C≡C-). Examples of alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, and the like. Unless otherwise specified, the term "alkynyl" can include "alkynylene" groups.

[0108] The terms "amido" and "carbamoyl", as used herein, alone or in combination, refer to an amino group, as described below, attached to the parent molecular moiety through a carbonyl group (or vice versa). The term "C-amido", as used herein, alone or in combination, refers to a -C(O)N(RR') group, where R and R' are as defined herein or as defined by a specifically enumerated designated "R" group. The term "N-amido", as used herein, alone or in combination, refers to a RC(O)N(R')- group, where R and R' are as defined herein or as defined by a specifically enumerated designated "R" group. The term "acylamino", as used herein, alone or in combination, encompasses an acyl group attached to the parent moiety through an amino group. One example of an "acylamino" group is acetylamino (CH3C(O)NH-).

[0109] The term "amino," as used herein, alone or in combination, refers to --NRR', where R and R' are independently selected from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally, R and R' may join to form a heterocycloalkyl, any of which may be optionally substituted.

[0110] The term "aryl" as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings, where such polycyclic ring systems are fused. The term "aryl" encompasses aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.

[0111] The terms "arylalkoxy" or "aralkoxy," as used herein, alone or in combination, refer to an aryl group attached to the parent molecular moiety through an alkoxy group.

[0112] The terms "arylalkyl" or "aralkyl," as used herein, alone or in combination, refer to an aryl group attached to the parent molecular moiety through an alkyl group.

[0113] The terms "arylalkanoyl" or "aralkanoyl" or "aroyl," as used herein, alone or in combination, refer to acyl radicals derived from aryl-substituted alkanecarboxylic acids, such as benzoyl, naphthoyl, phenylacetyl, 3-phenylpropionyl(hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.

[0114] The term aryloxy, as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an oxy.

[0115] The terms "benzo" and "benz" as used herein, alone or in combination, refer to the divalent radical CH= derived from benzene. Examples include benzothiophene and benzimidazole.

[0116] The term "carbamate," as used herein, alone or in combination, refers to an ester of carbamic acid (-NHCOO-), which may be attached to the parent molecular moiety through either the nitrogen or the acid terminus, and may be optionally substituted as defined herein.

[0117] The term "O-carbamyl" as used herein, alone or in combination, refers to a -OC(O)NRR' group, with R and R' as defined herein.

[0118] The term "N-carbamyl" as used herein, alone or in combination, refers to a ROC(O)NR'- group, with R and R' as defined herein.

[0119] The term "carbonyl" as used herein includes formyl [-C(O)H] when alone and in combination is a -C(O)- group.

[0120] The term "carboxyl" or "carboxy" as used herein refers to -C(O)OH or the corresponding "carboxylate" anion (such as in carboxylate salts). An "O-carboxy" group refers to a RC(O)O- group, where R is as defined herein. A "C-carboxy" group refers to a -C(O)OR group, where R is as defined herein.

[0121] The term "cyano," as used herein, alone or in combination, refers to --CN.

[0122] The term "cycloalkyl" or alternatively "carbocycle", as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic, or tricyclic alkyl group, where each cyclic moiety contains 3 to 12 carbon atom ring members, and may optionally be a benzo-fused ring system, optionally substituted as defined herein. In certain embodiments, the cycloalkyl may contain 5 to 7 carbon atoms. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl, and the like. As used herein, "bicyclic ring system" and "tricyclic ring system" are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene, and the like, as well as polycyclic (multi-center) saturated or partially saturated types. Examples of the latter type of isomers include, in general, bicyclo[1.1.1]pentane, camphor, adamantane, and bicyclo[3.2.1]octane.

[0123] The term "ester," as used herein, alone or in combination, refers to a carboxy group bridging two moieties which are joined at a carbon atom.

[0124] The term "ether," as used herein, alone or in combination, refers to an oxy group bridging two moieties which are joined at a carbon atom.

[0125] The terms "halo" or "halogen," as used herein, alone or in combination, refer to fluorine, chlorine, bromine, or iodine.

[0126] The term "haloalkoxy," as used herein, alone or in combination, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.

[0127] The term "haloalkyl" as used herein, alone or in combination, refers to an alkyl radical having the meaning as defined above in which one or more hydrogens have been replaced by halogen. In particular, monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals are included. As an example, monohaloalkyl radicals can have iodo, bromo, chloro or fluoro atoms in the radical. Dihalo and polyhaloalkyl radicals can have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. "Haloalkylene" refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (-CFH-), difluoromethylene (-CF2-), chloromethylene (-CHCl-), and the like.

[0128] The term "heteroalkyl," as used herein, alone or in combination, refers to a stable linear, branched, or combination thereof, which is fully saturated or contains one to three degrees of unsaturation, and which consists of the specified number of carbon atoms and one to three heteroatoms selected from N, O, and S, where the N and S atoms may be optionally oxidized and the N heteroatom may be optionally quaternized. The heteroatom may be located at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, for example, -CH2-NH-OCH3.

[0129] The term "heteroaryl" as used herein, alone or in combination, refers to a 3-15 membered unsaturated heteromonocyclic ring or a fused monocyclic, bicyclic, or tricyclic ring system, where at least one of the fused rings is aromatic containing at least one atom selected from N, O, and S. In certain embodiments, the heteroaryl can contain 1-4 heteroatoms as ring members. In further embodiments, the heteroaryl can contain 1-2 heteroatoms as ring members. In certain embodiments, the heteroaryl can contain 5-7 atoms. The term also encompasses fused polycyclic groups in which a heterocyclic ring is fused to an aryl ring, a heteroaryl ring is fused to another heteroaryl ring, a heteroaryl ring is fused to a heterocycloalkyl ring, or a heteroaryl ring is fused to a cycloalkyl ring. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl, and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl, and the like.

[0130] The terms "heterocycloalkyl" and, interchangeably, "heterocycle", as used herein, alone or in combination, refer to a saturated, partially unsaturated, or fully unsaturated (but non-aromatic), monocyclic, bicyclic, or tricyclic heterocyclic group, respectively, containing at least one heteroatom as a ring member, where each of said heteroatoms may be independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, said heterocycloalkyl may contain 1 to 4 heteroatoms as ring members. In further embodiments, said heterocycloalkyl may contain 1 to 2 heteroatoms as ring members. In certain embodiments, said heterocycloalkyl may contain 3 to 8 ring members in each ring. In further embodiments, said heterocycloalkyl may contain 3 to 7 ring members in each ring. In still further embodiments, said heterocycloalkyl may contain 5 to 6 ring members in each ring. "Heterocycloalkyl" and "heterocycle" are intended to include sulfone, sulfoxide, N-oxide of a tertiary nitrogen ring member, and carbocyclic fused and benzofused ring systems, and both terms also include systems in which a heterocycle is fused to an aryl group, as defined herein, or an additional heterocyclic group. Examples of heterocyclic groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. Unless specifically prohibited, a heterocycle group may be optionally substituted.

[0131] The term "hydroxy," as used herein, alone or in combination, refers to --OH.

[0132] The term "hydroxyalkyl," as used herein, alone or in combination, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.

[0133] The term "imino," as used herein, alone or in combination, refers to =N-.

[0134] The term "iminohydroxy" as used herein, alone or in combination, refers to =N(OH) and =NO-.

[0135] The phrase "in the backbone" refers to the longest contiguous or adjacent chain of carbon atoms beginning from the point of attachment of a group to a compound of any one of the formulas disclosed herein.

[0136] The term "isocyanato" refers to a -NCO group.

[0137] The term "isothiocyanato" refers to the group -NCS.

[0138] The phrase "linear chain of atoms" refers to the longest linear chain of atoms independently selected from carbon, nitrogen, oxygen, and sulfur.

[0139] The term "lower", as used herein, alone or in combination, means, unless otherwise specifically defined, containing from 1 to 6 carbon atoms (ie, C1-C6 alkyl).

[0140] The term "lower aryl," as used herein, alone or in combination, means phenyl or naphthyl, either of which may be optionally substituted as specified.

[0141] The term "lower heteroaryl," as used herein, alone or in combination, means either 1) a monocyclic heteroaryl containing 5 or 6 ring members, of which 1 to 4 of said ring members can be heteroatoms selected from N, O, and S, or 2) a bicyclic heteroaryl in which any of the fused rings contains 5 or 6 ring members, between which are 1 to 4 heteroatoms selected from N, O, and S.

[0142] The term "lower cycloalkyl," as used herein, alone or in combination, refers to a monocyclic cycloalkyl having 3 to 6 ring members (i.e., C3-C6 cycloalkyl). A lower cycloalkyl may be unsaturated. Examples of lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0143] The term "lower heterocycloalkyl," as used herein, alone or in combination, refers to a monocyclic heterocycloalkyl (i.e., C3-C6 heterocycloalkyl) having 3 to 6 ring members, of which 1 to 4 may be heteroatoms selected from N, O, and S. Examples of lower heterocycloalkyl include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl. Lower heterocycloalkyls may be unsaturated.

[0144] The term "lower amino," as used herein, alone or in combination, refers to --NRR', where R and R' are independently selected from hydrogen and lower alkyl, either of which may be optionally substituted.

[0145] The term "mercaptyl" as used herein, alone or in combination, refers to an RS-group, where R is as defined herein.

[0146] The term "mercapto," as used herein, alone or in combination, refers to an SH- group.

[0147] As used herein, the term "phosphate ester" refers to a phosphate ester, alone or in combination, which is a phosphate ester having the functional group P(=O)(OR X )(OR Y )(OR Z ), where R X , R Y , and R Z are independently selected from hydrogen and organic groups. The term may also refer to compounds that contain this functional group.

[0148] As used herein, the term "phosphodiester" refers to a compound that, alone or in combination, has the functional group P(=X)(OR X )(OR Y )(OH), where R X , and R Y is an organic group and X is selected from oxygen and sulfur.

[0149] The term "thiophosphate," as used herein, alone or in combination, refers to a phosphate functional group in which one or more oxygen atoms have been replaced with sulfur, and the term may also refer to compounds containing this functional group.

[0150] The term "thiolophosphate," as used herein, alone or in combination, refers to a phosphate functional group that contains a PSR moiety in place of a POR moiety, and the term may also refer to compounds that contain this functional group.

[0151] The term "thionophosphate," as used herein, alone or in combination, refers to a phosphate functional group in which the P=O moiety is replaced with a P=S moiety, and the term may also refer to compounds that contain this functional group.

[0152] For certain thiolophosphates and thionophosphates, the following tautomeric equilibria may occur: P(=S)(OR X )(OR Y )(OH)←→P(=O)(OR X )(OR Y )(SH)

[0153] The term "thiono" as used herein, alone or in combination, refers to ═S.

[0154] The term "nitro," as used herein, alone or in combination, refers to --NO.

[0155] The terms "oxy" or "oxa," as used herein, alone or in combination, refer to --O--.

[0156] The term "oxo" as used herein, alone or in combination, refers to =O.

[0157] The term "perhaloalkoxy" refers to an alkoxy group in which all of the hydrogen atoms have been replaced by halogen atoms.

[0158] The term "perhaloalkyl," as used herein, alone or in combination, refers to an alkyl group having all of the hydrogen atoms replaced by halogen atoms.

[0159] The terms "sulfonate," "sulfonic acid," and "sulfonic," as used herein, alone or in combination, refer to the -SO3H group and its anion (when the sulfonic acid is used in the salt form).

[0160] The term "sulfanyl" as used herein, alone or in combination, refers to --S--.

[0161] The term "sulfinyl" as used herein, alone or in combination, refers to -S(O)-.

[0162] The term "sulfonyl," as used herein, alone or in combination, refers to -S(O)2-.

[0163] The term "tautomer" as used herein refers to one of two or more isomers that rapidly interconvert, alone or in combination. Generally, this interconversion is fast enough that one individual tautomer is not isolated in the absence of the other tautomer. The ratio of the amounts of tautomers may vary depending on the solvent composition, ionic strength, and pH, as well as other solution parameters. The ratio of the amounts of tautomers may differ in a particular solution and in the microbial environment of a biomolecule binding site in said solution. Examples of tautomers known in the art include keto / enol, enamine / imine, and lactam / lactim tautomers. Examples of tautomers known in the art also include 2-hydroxypyridine / 2(1H)-pyridone and 2-aminopyridine / 2(1H)-iminopyridone tautomers.

[0164] As used herein, the term "predominantly one isomer" means that a compound contains at least about 85% of one isomer (e.g., enantiomer or diastereomer). For example, in certain embodiments, a compound may contain at least about 90% of one isomer. In certain embodiments, a compound may contain at least about 95% of one isomer. In certain embodiments, a compound may contain at least about 98% of one isomer. In certain embodiments, a compound may contain at least about 99% of one isomer. Similarly, the phrase "substantially free of other isomers" means that a compound contains at most about 15% of another isomer. For example, in certain embodiments, a compound contains at most about 10% of another isomer. In certain embodiments, a compound contains at most about 5% of another isomer. In certain embodiments, a compound contains at most about 2% of another isomer. In certain embodiments, a compound contains at most about 1% of another isomer.

[0165] Cyclic dinucleotides, including those specifically described herein, as well as isoforms (e.g., tautomers) of those specifically described herein, can be used in the practice of the present invention. Cyclic dinucleotides can be obtained using any suitable method. For example, cyclic dinucleotides can be made by chemical synthesis using nucleoside derivatives as starting materials. Cyclic dinucleotides can also be produced by in vitro synthesis using recombinant purified cGAMP synthase. Furthermore, the structure of such cyclic dinucleotides can be confirmed using analytical chemistry techniques. These techniques include, but are not limited to, nuclear magnetic resonance (both proton and other nuclei, and both 1D and 2D), X-ray crystallography, electromagnetic spectroscopy (including, but not limited to, the visible, infrared, and optical regions of the electromagnetic spectrum, and including, but not limited to, absorption, emission, and optical rotation), and mass spectrometry.

[0166] The cyclic dinucleotides provided herein can be represented by the following nomenclature: cyclic [X1(A-5')pX2(B-5')p], where X1 and X2 are the first and second nucleosides, A is the point of attachment of the first nucleoside (e.g., 2' or 3') linked to the 5' carbon of the second nucleoside via a phosphodiester bond, and B is the point of attachment of the second nucleoside (e.g., 2' or 3') linked to the 5' carbon of the first nucleoside. For example, according to this nomenclature, cyclic (A(2'-5')pG(3'-5')p] can be represented by the following formula: [ka] has.

[0167] The terms "thia" and "thio" as used herein, alone or in combination, refer to an -S- group or an ether where the oxygen is replaced with a sulfur. The oxidized derivatives of the thio group, namely sulfinyl and sulfonyl, are included in the definition of thia and thio.

[0168] The term "thiol" as used herein, alone or in combination, refers to a -SH group.

[0169] The term "sulfhydryl," as used herein, alone or in combination, refers to a -SH group.

[0170] The term "thiono," as used herein, alone or in combination, refers to a sulfur that is double bonded to a parent atom.

[0171] The term "thiocarbonyl" as used herein alone includes thioformyl-C(S)H and in combination is a -C(S)- group.

[0172] The term "N-thiocarbamyl" refers to a ROC(S)NR'- group, with R and R' as defined herein.

[0173] The term "O-thiocarbamyl" refers to a -OC(S)NRR' group, with R and R' as defined herein.

[0174] The term "thiocyanato" refers to the group -CNS.

[0175] The term "trihalomethanesulfonamide" refers to a X3CS(O)2NR- group, where X is a halogen and R is as defined herein.

[0176] The term "trihalomethanesulfonyl" refers to a X3CS(O)2- group where X is a halogen.

[0177] The term "trihalomethoxy" refers to a X3CO- group where X is a halogen.

[0178] Any definition herein can be used in combination with any other definition to describe a composite structural group.By convention, the latter element of any such definition is the element that is attached to the parent moiety.For example, the composite group alkylamide can represent an alkyl group that is attached to the parent molecule via an amide group, and the term alkoxyalkyl can represent an alkoxy group that is attached to the parent molecule via an alkyl group.

[0179] When a group is defined as "null," what is meant is that the group is absent.

[0180] The term "optionally substituted" means that the preceding group may be substituted or unsubstituted. When substituted, the substituents of the "optionally substituted" group may include, but are not limited to, one or more substituents independently selected from the following groups or the set of specific specified groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower halo, Alkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxy ester, lower carboxamide, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N3, SH, SCH3, C(O)CH3, CO2CH3, CO2H, pyridinyl, thiophene, furanyl, lower carbamate, and lower urea. When structurally feasible, two substituents may be joined together to form a fused 5-, 6-, or 7-membered carbocyclic or heterocyclic ring of 0 to 3 heteroatoms, for example, to form methylenedioxy or ethylenedioxy. Optionally substituted groups may be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at any level between fully and monosubstituted (e.g., -CH2CF3). When a substituent is recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed. When a substituent is qualified as "substituted," the substituted form is specifically intended. Additionally, where appropriate, different optional substituent sets may be defined for a particular moiety, and in these cases the optional substitution will often be as defined immediately following the phrase "optionally substituted with."

[0181] The terms R or R' appearing alone and without a number designation, unless otherwise defined, refer to a moiety selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycloalkyl, any of which may be optionally substituted. Such R and R' groups should be understood to be optionally substituted as defined herein. Regardless of whether an R group has a number designation, R, R', and R n All R groups, including (where n=(1, 2, 3, ... n)), all substituents, as well as all terms, should be understood to be independent of all others with respect to selection from a group. If any variable, substituent, or term (e.g., aryl, heterocycle, R, etc.) occurs more than one time in a formula or generic structure, its definition at each occurrence is independent of its definition at every other occurrence. One of skill in the art will further recognize that certain groups may be attached to a parent molecule or may occupy a position in the chain of elements from either end as depicted. For example, an unsymmetrical group such as -C(O)N(R)- may be attached to the parent moiety at either the carbon or the nitrogen.

[0182] Asymmetric centers exist in the compounds disclosed herein. These centers are represented by the symbols "R" or "S" depending on the configuration of the substituents around the chiral atom. It will be understood by one of skill in the art that any tetrahedral atom with non-identical substituents may have a chiral center. Such groups of atoms include, but are not limited to, carbon and phosphorus. It should be understood that the present invention encompasses all stereochemical isomers, including diastereomeric, enantiomeric, and epimeric forms, as well as d- and l-isomers, and mixtures thereof. Individual stereoisomers of the compounds can be prepared synthetically from commercially available starting materials that contain chiral centers, or by preparation of a mixture of enantiomeric products followed by separation, such as conversion to a diastereomeric mixture, followed by separation or recrystallization, chromatographic techniques, direct separation of the enantiomers on a chiral chromatographic column, or any other suitable method known in the art. Starting compounds of a particular stereochemistry are commercially available or can be made and resolved by techniques known in the art. Furthermore, the compounds disclosed herein may exist as geometric isomers. The present invention includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers, as well as the appropriate mixtures thereof. Furthermore, the compounds may exist as tautomers; all tautomers are provided by the present invention. In addition, the compounds disclosed herein may exist in unsolvated forms as well as solvated forms with pharma- ceutically acceptable solvents, such as water, ethanol, and the like. In general, solvated forms are considered equivalent to unsolvated forms.

[0183] The terms "R" and "S" will be understood by those of ordinary skill in the chemical arts to refer to the absolute stereochemistry at a given chiral tetrahedral atom using the Cahn-Ingold-Prelog prioritization rules. Chemical structures provided herein having chiral tetrahedral atoms encompass compounds having either "R" or "S" absolute stereochemistry at that atom, in the absence of either (a) an explicit "R" or "S" designation in the structure at that atom, or (b) an explicit wedge and dash designation of the bond to that atom, as would be understood by those of ordinary skill in the chemical arts, for purposes of indicating absolute stereochemistry.

[0184] "R P " and "S P " refers to the absolute stereochemistry at the phosphorus atom. For compounds that contain more than one phosphorus atom and therefore require more than one such term, the terms are listed in the same order as given for the phosphorus atom in the given name.

[0185] The term "bond" refers to a covalent bond between two atoms, or between two moieties when the atoms joined by the bond are considered to be part of a larger substructure. The bond may be a single, double, or triple bond, unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may or may not be present at that position.

[0186] As used herein, the term "supramolecular assembly," alone or in combination, refers to an assembly of molecules that are held together by non-covalent interactions. In some embodiments, the non-covalent interactions are hydrophobic interactions. In some embodiments, the non-covalent interactions are hydrogen bonding interactions. In some embodiments, the non-covalent interactions are electrostatic interactions between ions. In some embodiments, the molecules are amphiphilic in nature. In some embodiments, the supramolecular assembly includes both hydrophobic and hydrophilic regions. In some embodiments, the supramolecular assembly includes a lipid bilayer.

[0187] As used herein, the term "nanoparticles", alone or in combination, refers to particles that are larger than typical synthetic organic molecules. In some embodiments, the nanoparticles are greater than about 100 picometers in size. In some embodiments, the nanoparticles are greater than about 1 nanometer in size. In some embodiments, the nanoparticles are greater than about 10 nanometers in size. In some embodiments, the nanoparticles are greater than about 100 nanometers in size. In some embodiments, the nanoparticles are greater than about 1 micrometer in size. In some embodiments, the nanoparticles are greater than about 10 micrometers in size. In some embodiments, the nanoparticles are composed primarily of metals, including but not limited to gold, lead, and zinc. In some embodiments, the nanoparticles are composed of inorganic salts, including but not limited to cadmium selenide, zinc telluride, and silicon nitride. In some embodiments, the nanoparticles are uniform in composition. In some embodiments, the nanoparticles include both core and shell regions of different compositions.

[0188] The term "disease" as used herein is generally intended to be synonymous with, and is used interchangeably with, the terms "disorder," "syndrome," and "condition" (as in medical condition), all of which refer to an abnormal condition of the human or animal body or one of its organs that impairs the normal functioning, is usually manifested by noticeable signs and symptoms, and causes a decrease in the life span or quality of life of the human or animal.

[0189] The term "combination therapy" refers to the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in this disclosure. Such administration includes the co-administration of these therapeutic agents substantially simultaneously (e.g., in a single capsule having a fixed ratio of active ingredients, or in multiple separate capsules for each active ingredient). Moreover, such administration also includes the sequential use of each type of therapeutic agent. In either case, the treatment regimen will provide the beneficial effects of the drug combination in treating the condition or disorder described herein.

[0190] A typical test to determine whether a compound is a STING agonist is to administer the compound to a wild-type human or animal cell line and a corresponding cell line in which the STING-encoding gene has been genetically inactivated (e.g., a homozygous STING knockout cell line). STING agonists will induce type I interferon in wild-type cells but not in cells in which the STING-encoding gene has been inactivated.

[0191] As used herein, the term "STING agonist" is used to refer to a compound that induces activation of a STING-dependent pathway at least as effectively as bis-3',5'c-di-GMP. In some embodiments, a STING agonist induces activation of a STING-dependent pathway at least twice as effectively as bis-3',5'c-di-GMP. In some embodiments, a STING agonist induces activation of a STING-dependent pathway at least 5 times as effectively as bis-3',5'c-di-GMP. In some embodiments, a STING agonist induces activation of a STING-dependent pathway at least 10 times as effectively as bis-3',5'c-di-GMP. In some embodiments, a STING agonist induces activation of a STING-dependent pathway at least 20 times as effectively as bis-3',5'c-di-GMP. In some embodiments, a STING agonist induces activation of a STING-dependent pathway at least 50 times as effectively as bis-3',5'c-di-GMP. In some embodiments, a STING agonist induces activation of a STING-dependent pathway at least 100-fold more effectively than bis-3',5'c-di-GMP.

[0192] The phrase "therapeutically effective" is intended to qualify the amount of active ingredient used in the treatment of a disease or disorder or in the achievement of a clinical endpoint.

[0193] The term "therapeutically acceptable" refers to a compound (or a salt, prodrug, tautomer, zwitterionic form, etc.) that is suitable for use in contact with the tissues of a patient without undue toxicity, irritation, or allergic response, commensurate with a reasonable benefit / risk ratio, and is effective for its intended use.

[0194] As used herein, the terms "treating", "treatment" and the like refer to improving a disease to reduce, ameliorate or eliminate the cause of the disease, its progression, its severity, or one or more of its symptoms, or to beneficially alter the disease in a subject. References to "treating" a patient or "treatment" of a patient are intended to include prophylaxis. Treatment may be proactive in nature, i.e., to prevent the disease in a subject exposed to or at risk for the disease. Prevention of a disease may include complete protection from the disease, such as in the case of preventing infection by a pathogen, or may include prevention of the progression of the disease, e.g., from prediabetes to diabetes. For example, prevention of a disease does not mean the complete elimination of all effects associated with the disease at any level, but instead may mean preventing the symptoms of the disease to a clinically significant or detectable level. Prevention of a disease may also mean preventing the disease from progressing to a later stage of the disease.

[0195] The term "patient" is generally synonymous with the term "subject" and includes all mammals, including humans. Examples of patients include humans, farm animals such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.

[0196] The term "prodrug" refers to a compound that is more active in vivo. Certain compounds disclosed herein can also exist as prodrugs, as described in "Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology" (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compounds that readily undergo chemical changes under physiological conditions to provide the compounds. Additionally, prodrugs can be converted to the compounds by chemical or biochemical methods in an ex vivo environment. For example, a prodrug can be slowly converted to the compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because in some situations they may be easier to administer than the compound, or parent drug. A prodrug may be bioavailable by oral administration, for example, whereas the parent drug is not. Prodrugs may also have improved solubility in pharmaceutical compositions compared to the parent drug. Various types of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. One non-limiting example of a prodrug may be a compound that is administered as an ester ("prodrug"), but is subsequently metabolically hydrolyzed to the carboxylic acid, which is the active entity. Additional examples include peptidyl derivatives of compounds.

[0197] The compounds disclosed herein can be administered using a drug delivery vehicle.

[0198] As used herein, alone or in combination, the term "drug delivery vehicle" refers to a molecular assembly that includes a pharmacokinetically active compound and a second component that confers a pharmacokinetic benefit.

[0199] In some embodiments, the drug delivery vehicle comprises a pharma- ceutically active compound and a targeting moiety.

[0200] As used herein, the term "targeting moiety", alone or in combination, is used to refer to a moiety that aids in the delivery of a pharma- ceutical active compound to a biochemical target. In some embodiments, the pharma- ceutical active compound is covalently linked to the targeting moiety. In some embodiments, the pharma- ceutical active compound is covalently linked to the targeting moiety by a chemically labile bond. Non-limiting examples of chemically labile bonds used for this purpose include acetals, ketals, esters, and amides. In some embodiments, the pharma- ceutical active compound is non-covalently linked to the targeting moiety.

[0201] In some embodiments, the targeting moiety is a biomolecule. Biomolecules that can be used as targeting moieties include, but are not limited to, peptides, proteins, antibodies, nucleic acids, and naturally occurring hormones, cofactors, signaling molecules, and enzyme substrates. In some embodiments, the targeting moiety is a synthetic analog of a biomolecule. In some embodiments, the targeting moiety is a synthetic molecule. In some embodiments, the targeting moiety is a nanoparticle.

[0202] In some embodiments, the drug delivery vehicle comprises a pharma- ceutically active compound and a container moiety.

[0203] As used herein, alone or in combination, the term "container moiety" refers to a molecule or supramolecular structure that partially or completely houses a pharma- ceutical active compound.

[0204] In some embodiments, the container moiety is a single molecule, hi some embodiments, the container moiety is a nanoparticle.

[0205] In some embodiments, the container portion is a supramolecular assembly of non-covalently linked molecules. In some embodiments, the container portion is a liposome. In some embodiments, the container portion is a micelle. In some embodiments, the container portion is a vesicle. In some embodiments, the container portion comprises a phospholipid.

[0206] In some embodiments, the pharma- ceutical active compound is completely contained within the container portion. In some embodiments, the pharma- ceutical active compound is partially contained within the container portion. In some embodiments, the pharma- ceutical active compound is non-covalently associated with the container portion.

[0207] In some embodiments, the drug delivery vehicle comprises a selectivity moiety.

[0208] As used herein, the term "selectivity moiety," alone or in combination, refers to a molecule that allows for selective delivery to a particular region of a subject's body. In some embodiments, the selectivity moiety selectively delivers a drug delivery vehicle to an organ of interest. In some embodiments, the selectivity moiety selectively delivers a drug delivery vehicle to a tumor. In some embodiments, the selectivity moiety improves transport across biological membranes. In some embodiments, the selectivity moiety improves transport from the gastrointestinal tract to the bloodstream. In some embodiments, the selectivity moiety improves transport across the blood-brain barrier. A selectivity moiety can be a targeting moiety, or vice versa.

[0209] The compounds disclosed herein can exist as therapeutically acceptable salts. The present invention includes the above compounds in the form of salts, including acid addition salts. Suitable salts include salts formed with both organic and inorganic acids. Such acid addition salts will usually be pharma-ceutically acceptable. However, salts of non-pharma-ceutically acceptable salts may be useful in the preparation and purification of the compound in question. Base addition salts may also be formed and may be pharma-ceutically acceptable. For a more complete discussion of salt preparation and selection, see "Pharmaceutical Salts: Properties, Selection, and Use" (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).

[0210] The term "therapeutically acceptable salt" as used herein refers to a water- or oil-soluble or dispersible salt or zwitterionic form of a compound disclosed herein that is therapeutically acceptable as defined herein. The salt may be prepared during the final isolation and purification of the compound, or separately, by reacting the appropriate compound in the form of a free base with an appropriate acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isethionate), lactate, maleate, malonate, and the like. Salts include, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Basic groups in the compounds disclosed herein can also be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfate; decyl chlorides, bromides, and iodides, lauryl, myristyl, and steryl; and benzyl and phenethyl bromides. Examples of acids that can be used to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, and organic acids such as oxalic acid, maleic acid, succinic acid, and citric acid. Salts can also be formed by coordination of the compounds with alkali metal or alkaline earth metal ions. Thus, the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.

[0211] Base addition salts can be prepared during the final isolation and purification of the compounds by reacting the carboxyl group with a suitable base, such as a hydroxide, carbonate, or bicarbonate of a metal cation, or with ammonia or an organic primary, secondary, or tertiary amine. Therapeutically acceptable salt cations include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as non-toxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N'-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

[0212] Although it may be possible for the compounds of the subject invention to be administered as the raw chemical, they may also be provided as pharmaceutical formulations. Thus, provided herein are pharmaceutical formulations that include one or more of the specific compounds disclosed herein, or one or more pharma- ceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharma- ceutically acceptable carriers thereof, and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Appropriate formulations depend on the route of administration chosen. Any of the well-known techniques, carriers, and excipients as appropriate and understood in the art may be used. The pharmaceutical compositions disclosed herein may be manufactured by any method known in the art, for example, by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compressing processes.

[0213] Formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal, and topical (including dermal, buccal, sublingual, and ocular) administration, although the most suitable route may depend, for example, on the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art. In general, these methods include the step of bringing into association a compound of the subject invention or a pharma-ceutically acceptable salt, ester, tautomer, amide, prodrug, or solvate thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product into the desired formulation.

[0214] Formulations of the compounds disclosed herein suitable for oral administration can be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or an oil-in-water liquid emulsion. The active ingredient may also be presented as a bolus, electuary, or paste.

[0215] Pharmaceutical preparations that can be used orally include tablets, push-fit capsules made of gelatin, and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form, such as powder or granules, optionally mixed with a binder, inert diluent, or lubricant, surfactant, or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. Tablets can optionally be coated or scored, and can also be formulated so as to provide sustained or controlled release of the active ingredient therein. All preparations for oral administration should be in dosages suitable for such administration. Push-fit capsules can contain the active ingredient in admixture with a filler, such as lactose, a binder, such as starch, and / or a lubricant, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compound may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol. In addition, stabilizers may be added. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and / or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyes or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0216] The compounds may be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. Injectable preparations may be provided in unit dosage form, for example, in ampoules or in multi-dose containers, with added preservatives. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous media, and may contain formulatory agents, such as suspending, stabilizing and / or dispersing agents. The preparations may be provided in single-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in powder form or freeze-dried (lyophilized) condition, requiring only the addition of a sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind described above.

[0217] Preparations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compound, which may contain antioxidants, buffers, bacteriostats, and solutes that render the preparation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds, allowing for the preparation of highly concentrated solutions.

[0218] In certain embodiments, parenteral administration is facilitated using liposomes. Liposomes are vesicles formed from one or more layers of phospholipids. Liposomes contain both hydrophilic and hydrophobic regions and can be used to improve the pharmacokinetic properties of the formulation. In some embodiments, liposomes can contain one or more additional components such as peptidoglycan, lipopeptide, lipopolysaccharide, phosphorylated lipid A, acylated phosphatidylcholine, acylated glycerol, oligonucleotides, ceramide, retinoic acid, quaternary ammonium salts, anionic, cationic, and nonionic surfactants, lipoteichoic acid, resiquimod, imiquimod, and flagellin.

[0219] In addition to the above-mentioned preparations, the compound may be formulated as a depot preparation. Such long-acting preparations can be administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection.Thus, for example, the compound may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as sparingly soluble salts.

[0220] For buccal or sublingual administration, the compositions can take the form of tablets, lozenges, pastilles, or gels formulated in a conventional manner. Such compositions may contain the active ingredient in a flavored base, such as sucrose and acacia or tragacanth.

[0221] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.

[0222] Certain compounds disclosed herein can be administered locally, i.e., by non-systemic administration. This includes external application of the compounds disclosed herein to epithelium or buccal cavity, as well as instillation of such compounds into the ear, eye and nose, so that the compounds do not enter the bloodstream as much. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

[0223] Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation, such as gels, liniments, lotions, creams, ointments or pastes, as well as drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, 0.001% to 10% w / w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise 10% w / w. In other embodiments, it may comprise less than 5% w / w. In certain embodiments, the active ingredient may comprise 2% w / w to 5% w / w. In other embodiments, it may comprise 0.1% to 1% w / w of the formulation.

[0224] For administration by inhalation, the compound can be conveniently delivered from an insufflator, a nebulizer pressurized pack, or other convenient means for delivering an aerosol spray. The pressurized pack can contain a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. For pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compound according to the present invention can be in the form of a dry powder composition, for example, a powder mixture of the compound and a suitable powder base, such as lactose or starch. The powder composition can be provided in unit dosage form, for example, in capsules, cartridges, gelatin or blister packs, and the powder can be administered from the unit dosage form using an inhaler or insufflator.

[0225] Preferred unit dosage forms are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of an active ingredient.

[0226] It should be understood that in addition to the ingredients particularly mentioned above, the above formulations may include other agents conventional in the art having regard to the type of formulation in question; for example, those suitable for oral administration may include flavoring agents.

[0227] The compounds may be administered orally or by injection at a dose of 0.1 to 500 mg / kg per day. The dose range for adults is generally 5 mg to 2 g / day. Tablets or other presentation forms provided in discrete units may conveniently contain one or more compounds in such a dosage amount or multiples thereof that are effective, for example, a unit containing 5 mg to 500 mg, usually about 10 mg to 200 mg.

[0228] The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

[0229] The compound may be administered in various modes, for example, orally, topically, or by injection. The exact amount of compound administered to a patient may be the responsibility of the attending physician. The specific dose level for any particular patient may depend on a variety of factors, including the activity of the specific compound used, age, body weight, general health, sex, diet, time of administration, route of administration, excretion rate, drug combination, the exact disorder being treated, and the severity of the symptom or condition being treated. Also, the route of administration may vary depending on the condition and its severity.

[0230] In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharma- ceutically acceptable salt, ester, tautomer, or prodrug thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient when receiving one of the compounds described herein is hypertension, it may be appropriate to administer an antihypertensive drug in combination with the first therapeutic agent. Alternatively, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjunct (i.e., the adjunct may have minimal therapeutic benefit by itself, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Alternatively, by way of example only, the benefit experienced by the patient may be increased by administering one of the compounds described herein with another therapeutic agent (including a treatment regimen) that also has a therapeutic benefit. By way of example only, in the treatment of diabetes that includes administering one of the compounds described herein, an increased therapeutic benefit may occur by also providing the patient with another therapeutic agent for diabetes. In any case, regardless of the disease, disorder, or condition being treated, the overall benefit experienced by the patient may simply be the additive benefit of the two therapeutic agents, or the patient may experience a synergistic benefit.

[0231] In either case, the multiple therapeutic agents (at least one of which is a compound disclosed herein) can be administered in any order, or even simultaneously. If simultaneously, the multiple therapeutic agents can be provided in a single, combined form or in multiple forms (by way of example only, as a single pill or two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given in multiple doses. If not simultaneously, the timing between the multiple doses can be any period ranging from a few minutes to four weeks.

[0232] Thus, in another aspect, certain embodiments provide a method for treating a STING-mediated disorder in a human or animal subject in need of such treatment, comprising administering to said subject a compound disclosed herein in combination with at least one additional agent known in the art for the treatment of said disorder in an amount effective to reduce or prevent the disorder in said subject. In a related aspect, certain embodiments provide a therapeutic composition comprising at least one compound disclosed herein in combination with one or more additional agents for the treatment of a STING-mediated disorder.

[0233] In addition to being useful for human treatment, certain compounds and formulations disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, etc. More preferred animals include horses, dogs, and cats.

[0234] Autoimmune disorders In some embodiments, the compounds and pharmaceutical compositions of the present disclosure may be useful for treating autoimmune diseases and disorders. In some embodiments, the autoimmune disorder is selected from systemic lupus erythematosus, psoriasis, insulin-dependent diabetes mellitus, dermatomyositis, and Sjogren's syndrome. In some embodiments, the autoimmune disorder is multiple sclerosis.

[0235] In some embodiments, the compounds and pharmaceutical compositions of the present disclosure may be useful for treating immune system disorders or deficiencies.

[0236] In some embodiments, the compounds and pharmaceutical compositions of the present disclosure may be useful for treating a microbial or viral infection, hi some embodiments, the viral infection is hepatitis.

[0237] Inflammation and Inflammatory Diseases In some embodiments, the compounds and pharmaceutical compositions of the present disclosure may be useful for treating inflammation or an inflammatory disease or disorder, in some embodiments, the inflammatory disease or disorder is selected from skeletal muscle inflammation, vascular inflammation, neuroinflammation, digestive system inflammation, reproductive system inflammation, and ocular inflammation.

[0238] In some embodiments, the inflammatory disease or disorder is selected from the group consisting of: arthritis, tendonitis, synovitis, tenosynovitis, bursitis, fibromyalgia, epicondylitis, myositis, osteitis, blepharitis, cutis blepharochalasis, conjunctivitis, dacryoadenitis, keratitis, keratoconjunctivitis sicca (dry eye), scleritis, trichiasis, uveitis, encephalitis, Guillain-Barré syndrome, meningitis, neuromyotonia, narcolepsy, multifocal The disease is selected from sclerosis, myelitis, schizophrenia, arthrosclerosis, arthritis, phlebitis, vasculitis, lymphangitis, cholangitis, cholecystitis, enteritis, enterocolitis, gastritis, gastroenteritis, inflammatory bowel disease (such as Crohn's disease and ulcerative colitis), ileitis, proctitis, cervicitis, chorioamnionitis, endometritis, epididymitis, omphalitis, oophoritis, orchitis, salpingitis, tubo-ovarian abscess, urethritis, vaginitis, vulvitis, and vulvodynia.

[0239] In some embodiments, the inflammatory disease or disorder is selected from the group consisting of appendicitis, dermatitis, dermatomyositis, endocarditis, fibrositis, gingivitis, glossitis, hepatitis, hidradenitis suppurativa, iritis, laryngitis, mastitis, myocarditis, nephritis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, pneumonitis, prostatitis, pyelonephritis, and stomatitis, transplant rejection (related to organs such as kidney, liver, heart, lung, pancreas (e.g., islet cells), bone marrow, cornea, small intestine, skin allografts, skin allografts, and heart valve xenografts, serum sickness, and graft versus host disease), acute pancreatitis, chronic pancreatitis, acute respiratory distress syndrome, Sexary's syndrome, syndrome), congenital adrenal hyperplasia, non-dense thyroiditis, hypercalcemia associated with cancer, pemphigus, bullous herpetiform dermatitis, severe erythema multiforme, exfoliative dermatitis, seborrheic dermatitis, seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, hypersensistivity reactions, allergic conjunctivitis, keratitis, herpes zoster ophthalmicus, iritis and iridocyclitis. The treatment is selected from the group consisting of oiridocyclitis, retinochoroiditis, optic neuritis, symptomatic sarcoidosis, fulminant or disseminated pulmonary tuberculosis chemotherapy, idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, leukemia and lymphoma in adults, acute leukemia in children, regional enteritis, autoimmune vasculitis, multiple sclerosis, chronic obstructive pulmonary disease, solid organ transplant rejection, and sepsis. Preferred treatments include treatment of transplant rejection, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, type 1 diabetes, asthma, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, chronic lung disease, and inflammation associated with infectious conditions (e.g., sepsis).

[0240] In some embodiments, the compounds and pharmaceutical compositions of the present disclosure may be useful in treating autoimmune diseases or disorders that have an inflammatory component. In some embodiments, the autoimmune disease or disorder may be any of the following: acute universal alopecia, Behcet's disease, Chagas disease, chronic fatigue syndrome, dysautonomia, encephalomyelitis, ankylosing spondylitis, aplastic anemia, hidradenitis suppurativa, autoimmune hepatitis, autoimmune oophoritis, celiac disease, Crohn's disease, type 1 diabetes, giant cell arteritis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, Henoch-Schonlein purpura, Kawasaki disease, lupus erythematosus, microscopic colitis, microscopic polyarteritis, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, opsoclonus myoclonus syndrome, optic neuritis, ord's thyroiditis, orthopedic disease ... thyroiditis), pemphigus, polyarteritis nodosa, polymyalgia, rheumatoid arthritis, Reiter's syndrome, Sjogren's syndrome, temporal arteritis, Wegener's granulomatosis, warm autoimmune hemolytic anemia, interstitial cystitis, Lyme disease, morphea, psoriasis, sarcoidosis, scleroderma, ulcerative colitis, and vitiligo.

[0241] In some embodiments, the compounds and pharmaceutical compositions of the present disclosure may be useful for treating a neurodegenerative disease or disorder, in some embodiments, the neurodegenerative disease or disorder is selected from the following: Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis.

[0242] In some embodiments, the compounds and pharmaceutical compositions of the present disclosure can be administered before, during, or after vaccine administration. Benefits provided by co-administration include increased vaccine efficacy, reduced vaccine toxicity, or reduced vaccine side effects. In some embodiments, the vaccine can include inactivated or attenuated bacteria or viruses. In some embodiments, the vaccine can include purified antigens. In some embodiments, the vaccine can include live virus or bacterial delivery vectors that are recombinantly engineered to express or secrete antigens. In some embodiments, the vaccine can include antigen-presenting cells loaded with antigens. In some embodiments, the vaccine can include inactivated tumor cells.

[0243] cancer In some embodiments, the compounds of the present disclosure may be used to prevent or treat cancer.

[0244] In some embodiments, the compounds and pharmaceutical compositions of the present disclosure may be useful for the treatment or prevention of cancer, including but not limited to: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, AIDS-related cancers (Kaposi's sarcoma and lymphoma), anal cancer, appendix cancer, atypical teratoid / rhabdoid tumors, basal cell carcinoma, cholangiocarcinoma (including extrahepatic), bladder cancer, bone cancer (including osteosarcoma and malignant fibrous histiocytoma), brain tumors (e.g., astrocytoma, brain and spinal cord tumors, brain stem glioma, central nervous system atypical teratoid / rhabdoid tumor, central nervous system pulmonary blastoma, craniopharyngioma, ependymoblastoma, ependymomas, tumors, medulloblastoma, medulloepithelioma, intermediate pineal parenchymal tumor, supratentorial primitive neuroectodermal tumor, and pineal tumor), breast cancer, bronchial tumor, Burkitt's lymphoma, basal cell carcinoma, bile duct cancer (including extrahepatic), bladder cancer, bone cancer (including osteosarcoma and malignant fibrous histiocytoma), carcinoid tumor, cancer of unknown primary, central nervous system (e.g., atypical teratoid / rhabdoid tumor, embryonal tumor, and lymphoma), cervical cancer, childhood cancer, chordoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative disorder, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma (including mycosis fungoides and Cesariformes), syndrome), bile duct (extrahepatic), ductal carcinoma in situ (DCIS), embryonal carcinoma (central nervous system), endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, nasal neuroblastoma, Ewing's sarcoma family tumors, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, eye cancer (intraocular melanoma, retinoblastoma, etc.), fibrous histiocytoma of bone (including malignant and osteosarcoma), bladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumors (extracranial, extragonadal, ovarian), gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, heart Pancreatic cancer, Hepatocellular (liver) carcinoma, Histiocytosis, Langerhans cell, Hodgkin's lymphoma, Hypopharyngeal carcinoma, Intraocular melanoma, Islet cell tumors (endocrine, pancreatic), Kaposi's sarcoma, Kidney (including renal cell), Langerhans cell histiocytosis, Laryngeal cancer, Leukemia (including acute lymphocytic (ALL), acute myeloid (AML), chronic lymphocytic (CLL), chronic myeloid (CML), hairy cell leukemia), Lip and oral cavity cancer, Kidney cancer (primary), Lobular carcinoma in situ (LCIS), Lung cancer (non-small cell and small cell), Lymphoma (AIDS-related, Burkitt, Cutaneous T cell (mycosis fungoides and Sézary syndrome),Hodgkin, Non-Hodgkin, Primary Central Nervous System (CNS), Macroglobulinemia, Waldenstrom, Male Breast Cancer, Malignant Fibrous Histiocytoma and Osteosarcoma of Bone, Medulloblastoma, Melanoma (Including Intraocular (Eye)), Merkel Cell Carcinoma, Mesothelioma (Malignant), Metastatic Squamous Neck Cancer of Unknown Primary, Midline Carcinoma of the NUT Gene, Mouth Cancer, Multiple Endocrine Neoplasia Syndrome, Multiple Melanoma / Plasma Cell Neoplasms, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic / Myeloproliferative Neoplasms, Myeloid Leukemia, Chronic (CML), Myeloid Leukemia, Acute (AML), Myeloma and Multiple Myeloma, Myeloproliferative Disorders (Chronic), Nasal and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Oral Cavity Cancer Cancer), lip and oropharyngeal cancer, osteosarcoma and malignant fibrous histiocytoma of bone, ovarian cancer (e.g. epithelial, germ cell tumors, and low malignant potential tumors), pancreatic cancer (including islet cell tumors), papillomatosis, paraganglioma, paranasal sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, intermediate pineal parenchymal tumor, pineoblastoma and supratentorial primitive neuroectodermal tumor, pituitary tumor, plasma cell neoplasm / multiple melanoma, pleuropulmonary blastoma, pregnancy and breast cancer, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, renal pelvis and ureter, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcomas (Ewing sarcoma family tumors, Kaposi, soft tissue, uterine sarcoma) tumors, Sézary syndrome, skin cancer (e.g., melanoma, Merkel cell carcinoma, non-melanoma, etc.), small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous cell cervical carcinoma of unknown primary, metastatic, Stomach (Gastric) cancer, supratentorial primitive neuroectodermal tumor, T-cell lymphoma (skin, mycosis fungoides, and Sézary syndrome), testicular cancer, pharyngeal cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, trophoblastic tumor (gestational), unknown primary, special type childhood cancer, ureter and renal pelvis, transitional cell carcinoma, urethral cancer, uterine cancer, endometrium, uterine sarcoma, Waldenstrom's macroglobulinemia, or Wilms' tumor, or a variant thereof.

[0245] In some embodiments, the methods described herein are used to treat a condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I or a pharma- ceutically acceptable salt thereof, wherein the condition is cancer that has developed resistance to chemotherapeutic agents and / or ionizing radiation.

[0246] Vaccine adjuvants In some embodiments of the present invention, there is provided a compound of Formula (Ia), or a pharma- ceutically acceptable salt thereof, for use as a vaccine adjuvant.

[0247] In some embodiments, there is further provided a vaccine adjuvant comprising a compound of Formula (Ia), or a pharma- ceutically acceptable salt thereof.

[0248] In some embodiments, there is further provided an immunogenic composition comprising an antigen or antigen composition and a compound of Formula (Ia), or a pharma- ceutically acceptable salt thereof.

[0249] In some embodiments there is further provided an immunogenic composition comprising an antigen or antigenic composition and a compound of Formula (Ia), or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of disease.

[0250] In some embodiments, there is further provided a use of a compound of formula (Ia), or a pharma- ceutically acceptable salt thereof, for the manufacture of an immunogenic composition comprising an antigen or antigenic composition for the treatment or prevention of a disease. In some embodiments, there is further provided a method of treating or preventing a disease, comprising administering to a human subject suffering from or suspected of having a disease, an immunogenic composition comprising an antigen or antigenic composition and a compound of formula (Ia), or a pharma- ceutically acceptable salt thereof.

[0251] In some embodiments, there is further provided a vaccine composition comprising an antigen or antigenic composition and a compound of formula (Ia), or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a disease.In some embodiments, there is further provided a vaccine composition comprising an antigen or antigenic composition and a compound of formula (Ia), or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a disease.

[0252] In some embodiments there is further provided the use of a compound of formula (I), or a pharma- ceutically acceptable salt thereof, for the manufacture of a vaccine composition comprising an antigen or antigen composition for the treatment or prevention of a disease.

[0253] In some embodiments, there is further provided a method of treating or preventing a disease, comprising administering to a human subject suffering from or suspected of having a disease a vaccine composition comprising an antigen or antigen composition and a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0254] The compounds of formula (Ia) and their pharma- ceutically acceptable salts can also be formulated with vaccines as adjuvants to modulate their activity. Such compositions can contain one or more antibodies, or one or more antibody fragments, or antigenic components, including but not limited to proteins, DNA, live or dead bacteria, and / or viruses or virus-like particles. Such compositions can also contain one or more components with adjuvant activity, including but not limited to aluminum salts, oil and water emulsions, heat shock proteins, lipid A preparations and derivatives, glycolipids, other TLR agonists such as CpG DNA or similar agents, cytokines such as GM-CSF or IL-12 or similar agents.

[0255] Combination and Combined Therapies The compounds of the present invention can be used alone or in combination with other pharmacologic active compounds to treat conditions such as those mentioned above. The compounds of the present invention and other pharmacologic active compounds can be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially. Thus, in one embodiment, the present invention includes a method of treating a condition by administering to a subject a therapeutically effective amount of one or more compounds of the present invention and one or more additional pharmacologic active compounds.

[0256] In another embodiment, a pharmaceutical composition is provided that comprises one or more compounds of the present invention, one or more additional pharma- ceutically active compounds, and a pharma- ceutically acceptable carrier.

[0257] In another embodiment, the one or more additional pharma- ceutical active compounds are selected from anti-cancer agents, anti-proliferative agents, and anti-inflammatory agents.

[0258] The STING agonist compositions described herein are also optionally used in combination with other therapeutic agents selected for their therapeutic value with respect to the condition to be treated. Generally, in embodiments in which a combination therapy is used with the compounds described herein, the other agents do not need to be administered in the same pharmaceutical composition, and are optionally administered by another route due to different physical and chemical properties. After initial administration is generally performed according to established protocols, the dose, mode of administration, and time of administration are modified based on the observed effects. In certain instances, it is appropriate to administer the STING agonist compounds as described herein in combination with another therapeutic agent. By way of example only, the therapeutic effectiveness of a STING agonist is increased by the administration of another therapeutic agent (also comprising a therapeutic regimen) that also has a therapeutic benefit. Regardless of the disease, disorder, or condition being treated, the overall benefit experienced by the patient is simply the additive of the two therapeutic agents, or the patient experiences an increased (i.e., synergistic) benefit. Alternatively, if the compounds disclosed herein have side effects, it may be appropriate to administer an agent that alleviates those side effects; or the therapeutic effectiveness of the compounds described herein may be increased by administration of an adjuvant.

[0259] The therapeutically effective amount varies depending on when the agent is used in combination therapy. The method of experimentally determining the therapeutically effective dose of drugs and other agents for use in combination therapy regimens is a proven method. Combination therapy also includes periodic treatments that start and stop at different times to assist in the clinical management of patients. In any case, multiple therapeutic agents (one of which is a STING agonist as described herein) can be administered in any order or simultaneously. If simultaneously, multiple therapeutic agents are optionally provided in a single, unified form, or multiple forms (by way of example only, either as a single pill or two separate pills).

[0260] In some embodiments, one of the therapeutic agents is administered in multiple doses, or both are administered as multiple doses. If not simultaneous, the timing between the multiple doses optionally varies from more than 0 weeks to less than 12 weeks.

[0261] In addition, the combination method, composition and formulation should not be limited to the use of two drugs, and the use of multiple therapeutic combinations is also considered.The dosage regimen for treating, preventing or improving the condition that is sought to be alleviated is optionally changed according to various factors.These factors include the disorder that the subject suffers from, as well as the subject's age, weight, sex, diet and health condition.Therefore, the dosage regimen actually used in some embodiments varies greatly and therefore deviates from the dosage regimen described herein.

[0262] The pharmaceutical agents constituting the combination therapy disclosed herein are optionally in combined dosage forms or separate dosage forms intended for nearly simultaneous administration. The pharmaceutical agents constituting the combination therapy are optionally administered sequentially, with either agent being administered by a regimen requiring two-step administration. The two-step administration regimen optionally requires sequential administration of the active agents or separate spaced administration of the active agents. The time between the multiple administration steps can vary from minutes to hours, depending on the properties of each pharmaceutical agent, such as the potency, solubility, bioavailability, plasma half-life and kinetic profile of the pharmaceutical agent.

[0263] In another embodiment, the STING agonist is optionally combined with measures that provide additional benefits to the patient. The STING agonist and any additional therapeutic agent are optionally administered before, during, or after the onset of a disease or condition, and the timing of administration of the composition comprising the STING agonist varies in some embodiments. Thus, for example, the STING agonist is used as a prophylactic and is administered continuously to a subject prone to developing a condition or disease to prevent the onset of the disease or condition. The STING agonist and composition are optionally administered to the subject during or as soon as possible after the onset of symptoms. Although embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, modifications, and alternatives will occur to those skilled in the art without departing from the present invention. It should be understood that in some embodiments of the present invention, various alternatives to the embodiments described herein are used in carrying out the present invention.

[0264] STING agonists can be used in combination with anti-cancer agents, including, but not limited to, agents from the following classes: alkylating agents, antimetabolites, plant alkaloids and terpenoids, topoisomerase inhibitors, cytotoxic antibiotics, angiogenesis inhibitors, and tyrosine kinase inhibitors.

[0265] For use in cancer and neoplastic diseases, STING agonists may be optimally used in conjunction with one or more of the following non-limiting examples of anti-cancer agents: 1) Alkylating agents, including but not limited to carmustine, chlorambucil (LEUKERAN), cisplatin (PLATIN), carboplatin (PARAPLATIN), oxaliplatin (ELOXATIN), streptozocin (ZANOSAR), busulfan (MYLERAN), dacarbazine, isosphamide, lomustine (CCNU), melphalan (ALKERAN), procarbazine (MATULAN), temozolomide (TEMODAR), thiotepa, and cyclophosphamide (ENDOXAN); 2) Antimetabolites, including but not limited to cladribine (LEUSTATIN), mercaptopurine (PURINETHOL), thioguanine, pentostatin (NIPENT), cytosine arabinoside (cytarabine, ARA-C), gemcitabine (GEMZAR), fluorouracil (5-FU, CARAC), capecitabine (XELODA), leucovorin (FUSILEV), methotrexate (RHEUMATREX), and raltitrexed; 3) Taxanes, such as, but not limited to, docetaxel (TAXITERE) and paclitaxel (ABRAXANE, TAXOL); antimitotics (which are often plant alkaloids and terpenoids), including vinca alkaloids, such as vincristine (ONCOVIN), vinblastine, vindesine, and vinorelbine (NAVELBINE), or derivatives thereof; 4) Topoisomerase inhibitors, including but not limited to camptothecin (CTP), irinotecan (CAMPTOSAR), topotecan (HYCAMTIN), teniposide (VUMON), and etoposide (EPOSIN); 5) Cytotoxic antibiotics, including but not limited to actinomycin D (DACTINOMYCIN, COSMEGEN), bleomycin (BLENOXANE), doxorubicin (ADRIAMYCIN), daunorubicin (CERUBIDINE), epirubicin (ELLENCE), fludarabine (FLUDARA), idarubicin, mitomycin (MITOSOL), mitoxantrone (NOVANTRONE), plicamycin; 6) Aromatase inhibitors, including but not limited to aminoglutethimide, anastrozole (ARIMIDEX), letrozole (FEMARA), vorozole (RIVIZOR), and exemestane (AROMASIN); 7) Angiogenesis inhibitors, including but not limited to, genistein, sunitinib (SUTENT) and bevacizumab (AVASTIN); 8) Antisteroids and antiandrogens such as aminoglutethimide (CYTADREN), bicalutamide (CASODEX), cyproterone, flutamide (EULEXIN), nilutamide (NILANDRON); 9) Tyrosine kinase inhibitors, including but not limited to imatinib (GLEEVEC), erlotinib (TARCEVA), lapatinib (TYKERB), sorafenib (NEXAVAR), and axitinib (INLYTA); 10) mTOR inhibitors such as everolimus, temisirolimus (TORISEL), and sirolimus; 11) Monoclonal antibodies such as trastuzumab (HERCEPTIN) and rituximab (RITUXAN); 12) Amasacrine; Bacillus Calmette-Guerin (BCG) vaccine; Buserelin (ETILAMIDE); Chloroquine (ARALEN); Clodronate, pamidronate, and other bisphosphonates; Colchicine; Demethoxyviridine; Dichloroacetate; Estramustine; Filgrastim (NEUPOGEN); Fludrocortisone (FLORINEF); Goserelin (ZOLADEX); Interferon; Leucovorin; Leuprolide (LUPRON); Levamisole; Lonidamine; Mesna; Metformin; Mitotane (o,p'-DDD, L YSODREN); nocodazole; octreotide (SANDOSTATIN); perifosine; porfimer (especially in combination with photo- and radiation therapy); suramin; tamoxifen; titanocene dichloride; tretinoin; anabolic steroids such as fluoxymesterone (HALOTESTIN); estrogens such as estradiol, diethylstilbestrol (DES), and dienestrol; progestins such as medroxyprogesterone acetate (MPA) and megestrol; and other agents such as testosterone.

[0266] When used to treat multiple sclerosis, STING agonists may be optimally used in conjunction with one or more of the following non-limiting example medications: muscle relaxants such as glatiramer, corticosteroids, tizanidine (ZANAFLEX) or baclofen (LIORESAL), medications to reduce fatigue such as amantadine (SYMMETREL), modafinil (PROVIGIL), and medications to relieve depression, pain, and bladder or bowel control disorders.

[0267] In some embodiments, STING agonists may be optimally used in conjunction with one or more of the following non-limiting examples of immune checkpoint inhibitors: CTLA-4, PD-1, Tim-3, Vista, BTLA, LAG-3, and TIGIT pathway antagonists; PD-1 pathway blockers; PD-1 inhibitors, including but not limited to the anti-PD-1 antibodies nivolumab, pembrolizumab, or pidilizumab; the PD-1 inhibitor AMP-224; the anti-CTLA-4 antibody ipilimumab; and the anti-PD-L1 antibodies BMS-936559, MPDL3280A, MEDI4736, and avelumab.

[0268] In some embodiments, STING agonists may be optimally used with one or more of the following non-limiting example antibody therapeutics: muromonab-CD3, infliximab (REMICADE), adalimumab (HUMIRA), omalizumab (XOLAIR), daclizumab (ZENAPAX), rituximab (RITUXAN), ibritumomab (ZEVALIN), tositumomab (BEXXAR), cetuximab (ERBITUX), trastuzumab (HERCEPTIN), ADCETRIS, alemtuzumab (CAMPATH-1H), Lym-1 (ONCOLYM), ipilimumab (YERVOY), vitaxin, bevacizumab (AVASTIN), and abciximab (REOPRO).

[0269] If the subject is suffering from or at risk for suffering from an inflammatory disease, the STING agonist compounds described herein are optionally used in any combination with one or more agents or methods for treating the inflammatory condition. Therapeutic agents / treatments for treating autoimmune and / or inflammatory conditions include, but are not limited to, any of the following examples: 1) Corticosteroids, including but not limited to cortisone, dexamethasone, and methylprednisolone; 2) Nonsteroidal anti-inflammatory drugs (NSAIDs), including but not limited to ibuprofen, naproxen, acetaminophen, aspirin, fenoprofen (NALFON), flurbiprofen (ANSAID), ketoprofen, oxaprozin (DAYPRO), diclofenac sodium (VOLTAREN), diclofenac potassium (CATAFLAM), etodolac (LODINE), indomethacin (INDOCIN), ketorolac (TORADOL), sulindac (CLINORIL), tolmetin (TOLECTIN), meclofenamate (MECLOMEN), mefenamic acid (PONSTEL), nabumetone (RELAFEN), and piroxicam (FELDENE); 3) Immunosuppressants, including but not limited to methotrexate (RHEUMATREX), leflunomide (ARAVA), azathioprine (IMURAN), cyclosporine (NEORAL, SANDIMMUNE), tacrolimus, and cyclophosphamide (CYTOXAN); 4) CD20 blocking agents, including but not limited to rituximab (RITUXAN); 5) Tumor necrosis factor (TNF) blockers, including but not limited to etanercept (ENBREL), infliximab (REMICADE), and adalimumab (HUMIRA); 6) Interleukin-1 receptor antagonists, including but not limited to anakinra (KINERET); 7) Interleukin-6 inhibitors, including but not limited to tocilizumab (ACTEMRA); 8) Interleukin-17 inhibitors, including but not limited to AIN457; 9) Janus kinase inhibitors, including but not limited to tasocitinib; and 10) syk inhibitors, including but not limited to fostamatinib.

[0270] The compositions may also be administered in combination with radiation therapy, surgical therapy, immunotherapy, cryotherapy, gene therapy, or any other therapy known for use by those of skill in the art.

[0271] Combination therapy may be applied during the same period, or consecutively, or at overlapping intervals. Discontinuous combination therapy may alternate between two or more therapies. In some embodiments, it may be desirable to extend the period of administration of a particular therapy. In some situations, it may be desirable to shorten or extend the period between therapies.

[0272] List of abbreviations DCI = 4,5-dicyanoimidazole; DDTT = 3-((dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-5-thione; DMAP = 4-dimethylaminopyridine; DMOCP = 2-chloro-5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinane; DMTr = dimethoxytrityl = (4-methoxyphenyl)2(phenyl)methyl; Piv = pivaloyl = (CH3)3C-C(=O)-; NaOH = sodium hydroxide; M = moles; mL = milliliters; h = hours; min = minutes; HCl = hydrogen chloride; H2O = water; MS = mass spectrometry; ES+ = electrospray positive ionization; 1 H-NMR = proton nuclear magnetic resonance; 31P-NMR = phosphorus nuclear magnetic resonance; MHz = megahertz; H = hydrogen; RT = room temperature; °C = degrees Celsius; Br2 = bromine; NaHSO3 = sodium bisulfite; NMP = N-methyl-2-pyrrolidone; MW = microwave; KF = potassium fluoride; Pd(dppf)Cl2 = [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride; PE = petroleum ether; EtOAc = ethyl acetate; EA = ethyl acetate; CDCl3 = deuterated chloroform; DMSO-d6 = deuterated-6 dimethyl sulfoxide; CD3CN = deuterated acetonitrile; MeOH = methanol; D2O = deuterium oxide; prep-HPLC = preparative high pressure liquid chromatography, also known as preparative high performance liquid chromatography. (also known as chromatography); DMSO = dimethylsulfoxide; MeCN = acetonitrile; NH3 = ammonia; NH4OH = ammonium hydroxide; NIS = N-iodosuccinimide; DMF = dimethylformamide; K3PO4 = potassium phosphate tribasic; N2 = nitrogen; Py = pyridine; THF = tetrahydrofuran; TEA = triethylamine; TBSCl = tert-butyldimethylsilyl chloride; TEAB = tetraethylammonium bicarbonate; TMSCl = chlorotrimethylsilane;

[0273] TFA = trifluoroacetic acid; DCM = dichloromethane; K2CO3 = potassium carbonate; ul = microliter.

[0274] General synthetic methods for preparing compounds The following schemes can be used to practice the invention.

[0275] [ka] The compounds disclosed herein can be synthesized by using the general synthetic procedure shown in Scheme I, with variations that will be apparent to one of skill in the art. A nucleotide or nucleotide analog 101 bearing an unprotected 5' hydroxyl is coupled to a nucleotide or nucleotide analog 102 bearing a phosphoramidite moiety at its 2' hydroxyl using pyridinium fluoride. Oxidative sulfurization of the intermediate phosphite with DDTT attaches R to the phosphorothioate center. P and S P A mixture of diastereoisomers is given.

[0276] In the third step, the DMTr group on the fragment obtained from 102 was removed using dichloroacetic acid. Intermediate 103 was then cyclized with DMOCP and subjected to oxidative sulfurization using Beaucage reagent (3H-1,2-benzodithiol-3-one 1,1-dioxide). Depending on the stereochemistry at the newly formed phosphorothioate center, R P and S P A mixture of stereoisomers can be obtained. Based on previous literature (Gaffney, BLet al. Org. Lett. 2010, 12(14), 3269-3271; Zhao, J. et al. Nucleosides Nucleotides Nucl Acids 2009, 28, 352-378; Battistini, C. et al. Tetrahedron 1993, 49, 1115-1132.), the stereochemistry at this center is often, but not always, R P and is shown as (R) in Scheme 1. Removal of the cyanoethyl group of 104 with ammonia, followed by removal of the silyl protecting group of 105 with fluoride completes the synthesis. Cyclic dinucleotide 106 is obtained as a mixture of diastereoisomers, typically with the R at the phosphorothioate center based on the aforementioned literature. P R P and S P R PIt is also possible to obtain three or more diastereoisomers in some cases. The diastereoisomers can be separated and obtained in substantially pure form by reversed-phase HPLC purification. If desired, the anionic form can be obtained by treatment with an ion exchange resin. In this way, the disodium salt can be obtained, but is not limited to this. EXAMPLES

[0277] The present invention is further illustrated by the following examples.

[0278] Intermediate A (2R,3R,4R,5R)-2-(4-benzamido-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite [ka] Step 1 [ka] (2R,3R,4S,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol In a pressure-safe steel vessel, a mixture of (2R,3R,4S,5R)-2-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (7.0 g, 24.5 mmol) and 7N NH3 in MeOH (70 mL) was stirred at 110° C. for 16 h. The mixture was allowed to cool to RT and the volatiles were removed under reduced pressure. Ten batches of this reaction were run in parallel. The residues were combined and triturated with MeOH (500 ml) to give the title compound as an off-white solid.

[0279] Step 2 [ka] N-(7((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide To a solution of the product from the previous step (65.2 g, 245 mmol) in pyridine (1.14 L) at 0 °C, TMSCl (119.8 g, 1.10 mol, 4.5 eq) was added dropwise over 30 min. The mixture was stirred at 0 °C for an additional 30 min, after which BzCl (6 g, 34.9 mmol, 1.5 eq) was added dropwise. The resulting mixture was stirred at RT for 16 h, cooled to 0 °C and quenched with H2O (200 mL) followed by 25% aq. NH4OH (500 mL). The volatiles were removed under reduced pressure and the residue was diluted with H2O (1.5 L) and then extracted with EtOAc (3 x 2.0 L). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (DCM:MeOH=20:1) to give the title compound (60.7 g, 0.164 mmol, 67% for two steps). MS(ES + ) C 18 H 19 N4O5 theoretical value: 371, measured value: 370.8 [M+H] + ; 1 H-NMR (400MHz, DMSO-d6) δ ppm 11.15(s,1H),8.61(s,1H),8.07(d,J=7.4Hz,2H),7.74(d,J=3.8Hz,1H),7.6 1-7.67(m,1H),7.52-7.58(m,2H),6.69(d,J=3.6Hz,1H),6.24(d,J=6.4Hz,1H ),5.38(d,J=6.4Hz,1H),5.18(d,J=4.8Hz,1H),5.08(t,J=5.5Hz,1H),4.43( q,J=6.1Hz,1H),4.09-4.15(m,1H),3.93(q,J=3.6Hz,1H),3.52-3.68(m,2H).

[0280] Step 3 [ka] N-(7((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide To a solution of the product from the previous step (60.0 g, 162.0 mmol) in pyridine (420 mL) was added DMTrCl (65.87 g, 194.4 mol, 1.2 eq). The mixture was stirred at RT °C for 16 h, diluted with CHCl (1.0 L) and then washed with NaHCO (2 x 500 mL), H0 (500 mL) and brine (500 mL). The organic layer was dried over anhydrous NaSO, filtered and concentrated under reduced pressure. The residue was purified by SiO gel chromatography (5 / 1 petroleum ether / EtOAc to 100% EtOAc) to give the title compound (89.3 g, 132.8 mmol, 82%) as a white foam.

[0281] Step 4 [ka] N-(7((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-(tert-butyldimethylsilyloxy)-4-hydroxy-tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (A-4a) and N-(7((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-hydroxy-4-(tert-butyldimethylsilyloxy)-tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (A-4b) To a mixture of the product from the previous step (55 g, 81.76 mmol) and AgNO3 (22.92 g, 134.9 mmol, 22.7 mL, 1.65 eq) in THF (400 mL) was added TBSCl (78.75 g, 522.48 mmol, 1.76 eq). The reaction mixture was stirred at RT for 5 h, filtered and then concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (petroleum ether / EtOAc = 10 / 1 to 2 / 1) to give A-4a (70 g, 88.9 mmol, 54.4%) and A-4b (7 g, 8.89 mmol, 5.4%). A-4a: 1 H-NMR(400MHz,DMSO-d6)δ ppm 11.16(br s,1H),8.58(s,1H),8.07(d,J=7.7Hz,2H),7.52-7.67(m,4H),7.42(d,J=7.7Hz,2H),7.22-7.32(m,7H),6.88(d,J=8.8Hz,4H),6. 69(d,J=3.8Hz,1H),6.30(d,J=5.4Hz,1H),5.12(d,J=5.8Hz,1H),4.59(t,J=5.3Hz,1H),4.07-4.21(m,2H),3.73(s,6H),3.28(br s,2H),0.75(s,9H),-0.04(s,3H),-0.16(s,3H). A-4b: 1 H-NMR(400MHz,DMSO-d6)δ ppm 11.76(brs,1H),8.59(s,1H),8.07(d,J=7.8Hz,2H),7.61-7.66(m,2H),7.52-7.57(m,2H),7.38(br d,J=7.8Hz,2H),7.19-7.32(m,7H),6.86(d,J=8.7Hz,4H),6.68(d,J=3.6Hz,1H),6.21(d,J=5.6Hz,1H),5.38(br d,J=5.9Hz,1H),4.57(br d,J=5.1Hz,1H),4.34(t,J=4.4Hz,1H),4.00(br d,J=4.1Hz,1H),3.72(s,6H),3.30-3.39(m,1H),3.12-3.16(m,1H),3.14(br dd,J=4.7,10.4Hz,1H),0.84(s,9H),0.08(s,3H),0.03(s,3H).

[0282] Step 5 [ka] (2R,3R,4R,5R)-2-(4-benzamido-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite To a solution of A-4b (10.0 g, 12.71 mmol) in CHCl (100 mL) was added 3-((bis(diisopropylamino)phosphanyl)-oxy)propanenitrile (4.21 g, 14 mmol, 1.1 eq) and DCI (2.25 g, 19.07 mmol, 1.5 eq). The mixture was stirred at RT for 5 h, diluted with CHCl (100 mL) and then washed with saturated NaHCO (3×100 mL). The organic layer was dried over NaSO, filtered and concentrated under reduced pressure. The residue was purified by SiO gel chromatography (petroleum ether / EtOAc = 10 / 1 to 3 / 1; 0.5 TEA) to give the title compound (10.0 g, 9.72 mmol, 76%) as a white foam. 1 H-NMR(400MHz,CD3CN)δ ppm 9.23(br s,1H),8.52(br s,1H),8.01(br d,J=5.8Hz,2H),7.60-7.68(m,1H),7.51-7.58(m,2H),7.40-7.50(m,3H),7.18-7.34(m, 7H),6.79-6.92(m,5H),6.34-6.48(m,1H),4.97-4.70(m,1H),4.63-4.48(m,1H),4.13(br d,J=3.9Hz,1H),3.84-3.69(m,7H),3.62-3.41(m,4H),3.27-3.15(m,1H),2.58(t,J=6.2Hz,1H),2 .41(t,J=6.2Hz,1H),1.12-1.03(m,9H),0.91-0.84(m,12H),0.13(d,J=16.2Hz,3H),0.05(s,3H); 31P NMR(162MHz,CD3CN)δ ppm 149.92,149.53.

[0283] Intermediate B (2R,3R,4R,5R)-5-(4-benzamido-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)tetrahydrofuran-3-ylphosphonic acid hydrogen [ka] Step 1 [ka] (2R,3R,4R,5R)-5-(4-benzamido-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-ylphosphonic acid hydrogen salt Phosphorous acid (15.63 g, 190.6 mmol, 15 eq) was coevaporated three times with anhydrous pyridine (5 mL) and then dissolved in anhydrous pyridine (75 mL) with heating to about 45° C. The mixture was allowed to cool to RT. A-4a (10.0 g, 12.7 mmol) was added and the mixture was cooled to 0° C. Pivaloyl chloride (15.32 g, 127.07 mmol, 10.0 eq) was added slowly at 0° C. and the resulting mixture was allowed to warm to RT and stirred for 16 h. The reaction mixture was then quenched with 1 Maq. TEAB (100 mL) and extracted with EtOAc (3×1000 mL). The combined organic layers were washed with 0.5 Maq. TEAB (100 mL) and brine (1000 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (CH2Cl2 / MeOH=50 / 1) to give the title compound as a white foam (8.0 g, 8.38 mmol, 66%).

[0284] Step 2 [ka] (2R,3R,4R,5R)-5-(4-benzamido-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)tetrahydrofuran-3-ylphosphonic acid hydrogen The product from the previous step (40.0 g, 42.01 mmol) and H2O (4.0 g, 222 mmol, 4.0 mL, 5.3 eq) were added to a solution of Cl2CHCOOH in CH2Cl2 (6% v / v, 400 mL) and the reaction mixture was stirred at RT for 0.5 h before being washed with H2O (4 x 200 mL). The organic layer was dried over anhydrous Na2SO4 and filtered. SiO2 gel (80 g, previously treated with TEA) was combined with the filtrate and the mixture was concentrated under reduced pressure to give a loose SiO2 gel powder. The residue was purified by SiO2 gel column chromatography (CH2Cl2 / MeOH = 50 / 1 to 30 / 1) to give the title compound as a white solid (15.0 g, 23.08 mmol, 55%). MS(ES + ) C 24 H 34 N4O7PSi Theoretical value: 549, Measured value: 549.1 [M+H] + ; 1 H-NMR(400MHz,400MHz,DMSO-d6)δ ppm 11.15(br s,1H),8.49-8.74(m,1H),8.08(d,J=7.6Hz,2H),7.78(d,J=3.6Hz,1H),7.60-7.67(m,1H),7.51-7 .57(m,2H),6.74(d,J=3.6Hz,1H),6.28(d,J=6.2Hz,1H),5.75(s,1H),4.56-4.74(m,2H),4.16(br s,1H),3.61-3.76(m,2H),3.03(q,J=7.2Hz,5H),1.19(t,J=7.4Hz,7H),0.69(s,9H),-0.09(s,3H),-0.27(s,3H); 31 P NMR(162MHz,DMSO-d6)δ ppm 0.72.

[0285] Intermediate C (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-yl hydrogen phosphonate [ka] Step 1 [ka] N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-fluoro-4-hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide To a solution of N-(9-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide (35 g, 93.7 mmol) in pyridine (180 mL) was added DMTrCl (38.12 g, 112.5 mmol, 1.2 eq) and the resulting mixture was stirred at RT for 16 h. The mixture was then diluted with CHCl (800 mL) and then washed with saturated NaHCO (2×400 mL) and brine (400 mL). The organic layer was dried over anhydrous NaSO, filtered and then concentrated under reduced pressure. The residue was purified by SiO gel chromatography (petroleum ether / EtOAc = 10 / 1 to 1 / 4) to give the title compound (53.0 g, 78.4 mmol, 84%) as a white solid. 1H-NMR(400MHz,DMSO-d6)δ ppm 11.26(br s,1H),8.74(s,1H),8.62(s,1H),8.05(d,J=7.4Hz,2H),7.60-7.72(m,1H),7.48-7.58(m,2H),7.32(d,J=7.2Hz,2H),7.14-7.24( m,7H),6.80(dd,J=6.2,8.7Hz,4H),6.43(d,J=20.0Hz,1H),5.73-5.85(m,1H),5.61(d,J=4.4Hz,1H),4.76-4.99(m,1H),4.14(br d,J=5.4Hz,1H),3.64-3.79(m,7H),3.19-3.33(m,2H).

[0286] Step 2 [ka] (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluorotetrahydrofuran-3-yl hydrogen phosphonate Phosphorous acid (18.2 g, 222 mmol, 15 eq) was coevaporated three times with anhydrous pyridine (15 mL) and then dissolved in anhydrous pyridine (150 mL) with heating. The mixture was allowed to cool to RT. The product from the previous step (10 g, 14.8 mmol) was added and the resulting mixture was cooled to 0° C. Pivaloyl chloride (17.85 g, 148 mmol, 10 eq) was added slowly at 0° C. and the resulting mixture was allowed to warm to RT and then stirred for 16 h. The reaction mixture was then quenched with 1 M aqueous TEAB (150 mL) and extracted with EtOAc (3×900 mL). The combined organic layers were washed with 0.5 M aqueous TEAB (900 mL), brine (900 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (CH2Cl2 / MeOH=50 / 1 to 20 / 1; 1% TEA) to give the title compound as a white foam (38 g).

[0287] Step 3 [ka] (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-yl hydrogen phosphonate The product from the previous step (38 g, 45.19 mmol) and HO (4.0 g, 222 mmol, 4.0 mL, 5 eq) were added to a solution of ClCHCOOH in CHCl (6% v / v, 380 mL) and the reaction mixture was stirred at RT for 0.5 h. The reaction mixture was filtered to obtain a red solid, which was washed with CHCl (2×20 mL) to give the title compound as a white solid (15 g, 30.87 mmol, 68%). 1 H-NMR(400MHz,DMSO-d6)δ ppm 11.24(br s,1H),8.78(s,1H),8.73(s,1H),8.02-8.08(m,2H),7.76(d,J=1.2Hz,0.5H),7.62-7.68(m,1H),7.53-7.59(m,2H),6.69(s,1H),6.46(dd,J =3.2,16.6Hz,1H),6.07(d,J=1.4Hz,0.5H),5.87-5.91(m,1H),5.73-5.78(m,1H),5.17-5.28(m,1H),4.22-4.28(m,1H),3.64-3.84(m,2H).

[0288] Intermediate D (2R,3R,4R,5R)-2-(6-benzamido-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite [ka] Step 1 [ka] N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide To a solution of N-(9-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide (100 g, 269.3 mmol) in pyridine (500 mL) at 0° C. was added DMAP (1.64 g, 13.46 mmol, 0.05 eq) and DMTrCl (100.4 g, 296.2 mmol, 1.1 eq). The reaction mixture was stirred at RT for 16 h before being quenched by addition of MeOH (500 mL). After removal of volatiles under reduced pressure, the residue was purified by SiO2 gel chromatography (1 / 1 petroleum ether / EtOAc to 100% EtOAc) to give the title compound as a white foam (150 g, 223 mmol, 83%).

[0289] Step 2 [ka] N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-(tert-butyldimethylsilyloxy)-4-hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide (D-2a) and N-(9((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-(tert-butyldimethylsilyloxy)-3-hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide (D-2b) To a solution of the product from the previous step (200 g, 296.9 mmol) in THF (800 mL) and pyridine (15 mL), AgNO3 (83.2 g, 489.8 mmol, 82 mL, 1.65 eq) and TBSCl (78.7 g, 522.5 mmol, 1.76 eq) were added and the mixture was stirred at RT for 16 h. The reaction mixture was filtered, diluted with H2O (1.0 L) and then extracted with EtOAc (3 x 1.0 L). The combined organic layers were washed with brine (2 x 1.0 L), dried over anhydrous Na2SO4 and then concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (petroleum ether / EtOAc = 3 / 1 to 1 / 1) to give D-2a (114 g, 145 mmol, 49%) and D-2b (53 g, 68 mmol, 23%).

[0290] Step 3 [ka] (2R,3R,4R,5R)-2-(6-benzamido-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite To a solution of D-2b (19.0 g, 24.1 mmol) in MeCN (200 mL) at 0° C., 3-((bis(diisopropylamino)phosphanyl)-oxy)propanenitrile (7.99 g, 26.5 mmol, 1.1 eq) and DCI (3.42 g, 28.9 mmol, 1.2 eq) were added and the resulting mixture was stirred at RT under N2 atmosphere for 3 h. After removing the volatiles under reduced pressure, the residue was purified by SiO2 gel chromatography (petroleum ether / EtOAc = 4 / 1 to 1.5 / 1; 1% TEA) to give the title compound as a white foam (20.5 g, 20.74 mmol, 86%). MS(ES + ) C 53 H 67 N7O8PSi Theoretical value: 988, Measured value: 987.8 [M+H] + ; 1H-NMR(400MHz,CD3CN)δ ppm 8.57(s,1H),8.26(s,1H),7.91(br d,J=7.6Hz,2H),7.57(m,1H),7.47-7.49(m,2H),7.17-7.21(m,9H),6.73-6.76(m ,4H),6.10-6.19(m,1H),5.10-5.14(m,1H),4.64-4.68(m,1H),4.10-4.14(m,1H) ,3.25-3.75(m,7H),3.40-3.51(m,4H),3.15-3.18(m,1H),2.58(t,J=6.0Hz,1H), 2.41(t,J=6.0Hz,1H),1.03-1.06(m,9H),0.76-0.86(m,12H),0.00-0.93(m,6H); 31 P NMR(162MHz,CD3CN)δ ppm 150.32,149.58.

[0291] Intermediate E (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)tetrahydrofuran-3-ylphosphonic acid hydrogen triethylammonium salt [ka] Step 1 [ka] (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-(tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl(2-cyanoethyl)phosphonic acid hydrogen To a solution of (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite (25 g, 25.3 mmol) in MeCN (12 mL) was added HO (912 mg, 50.6 mmol, 2.0 eq) and pyridinium trifluoroacetate (5.86 g, 30.36 mmol, 1.2 eq) and the resulting mixture was stirred at RT for 5 min. tert-Butylamine (1.85 g, 25.3 mmol, 1.0 eq) was added and the resulting mixture was stirred at RT for a further 25 min before being concentrated under reduced pressure to give the title compound (23.4 g) as a white foam, which was used in the next step without further purification.

[0292] Step 2 [ka] (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)tetrahydrofuran-3-ylphosphonic acid hydrogen The crude product from the previous step (23.4 g, 25.3 mmol) was added to a solution of Cl2CHCOOH in CH2Cl2 (6% v / v, 200 mL). H2O (2.28 g, 126 mmol, 5.0 eq) was added and the resulting mixture was stirred at RT for 20 min. The reaction mixture was quenched by addition of pyridine (30 mL) at RT and then concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (CH2Cl2 / MeOH = 20 / 1 to 5 / 1) to give the title compound (15 g, 24.1 mmol).

[0293] Step 3 [ka] (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)tetrahydrofuran-3-ylphosphonic acid hydrogen tetraethylammonium salt The product from the previous step was dissolved in MeOH (100 mL) and added to TEA resin (50 g; DOWEX® 50WX2-H + Then, 1N aq. TEA; followed by 1N aq. TEA; again with 1N aq. TEA; then washed with MeOH) was added and the mixture was stirred at RT for 0.5 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give the title compound as the TEA salt (yellow solid; 15 g, 23 mmol, 95%). 1 H-NMR(400MHz,DMSO-d6)δ ppm 8.57(s,1H),8.26(s,1H),7.91(br d,J=7.6Hz,2H),7.57(m,1H),7.47-7.49(m,2H),7.17-7.21(m,9H),6.73-6.76(m ,4H),6.10-6.19(m,1H),5.10-5.14(m,1H),4.64-4.68(m,1H),4.10-4.14(m,1H) ,3.25-3.75(m,7H),3.40-3.51(m,4H),3.15-3.18(m,1H),2.58(t,J=6.0Hz,1H), 2.41(t,J=6.0Hz,1H),1.03-1.06(m,9H),0.76-0.86(m,12H),0.00-0.93(m,6H).

[0294] Intermediate F (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4-chloro-2-(hydroxymethyl)tetrahydrofuran-3-yl hydrogen phosphonate [ka] Step 1 [ka] A mixture of (2R,3S,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-5-((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-3-yl trifluoromethanesulfonate (69.0 g, 0.11 mol, 1.0 eq) and LiCl (51.2 g, 1.21 mol, 11.0 eq) in DMF (600 mL) was heated at 50° C. for 1.5 h. The reaction mixture was diluted with DCM (500 mL) and washed with H2O (300 mL×3). The organic layer was dried over Na2SO4, filtered, and then concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (PE / EtOAc=1:1) to give the title compound (46.0 g, 89.5 mmol, 81.4% yield) as a yellow solid. 1 H NMR(400MHz CDCl3)δ ppm 8.30-8.38(m,1H),8.06(s,1H),6.20(d,J=5.9Hz,1H),5.82-5.95(m,2H),4.96-5.04(m,1H),4.56-4.63(m,1H),4.17(q,J=3.5H) z,1H),3.96(dd,J=11.4,4.3Hz,1H),3.77(dd,J=11.4,3.0Hz,1H),0.92(d,J=13.9Hz,18H),0.14(d,J=8.8Hz,6H),0.08(s,6H).

[0295] Step 2 [ka] To a solution of the product from the previous step (46.0 g, 89.4 mmol, 1.0 eq) in Py (460 mL) at 0 °C under N2, BzCl (25.2 g, 179 mmol, 20.5 mL, 2.0 eq) was added dropwise and the resulting mixture was stirred at 25 °C for 16 h. The reaction was diluted with H2O (200 mL) and extracted with EtOAc (200 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and then concentrated under reduced pressure to give N-benzoyl-N-(9-((2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-chlorotetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide (60.0 g) as a yellow oil, which was used in the next step without further purification. MS (ES) + ) C 36 H 48 ClN5O5Si2 Theoretical value: 721, Measured value: 722 [M+H] + ;

[0296] Step 3 [ka] To a solution of the product from the previous step (60.0 g, 97 mmol, 1.0 eq) in THF (600 mL) was added TBAF (1 M in THF, 290 mL, 3.0 eq). The mixture was then stirred at 25° C. for 16 h. Removal of the volatiles under reduced pressure afforded N-benzoyl-N(9-((2R,3R,4R,5R)-3-chloro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide (48.0 g) as a yellow oil, which was used in the next step without further purification. MS (ES) + ) C 24 H 20 ClN5O5 theoretical value: 493, measured value: 494 [M+H] + ;

[0297] Step 4 [ka] To a solution of the product from the previous step (48.0 g, 97.2 mmol, 1.0 eq) in THF (500 mL) was added NH3.H2O (28% aq, 8.0 mL, 7.28 g, 54.0 mmol, 0.5 eq). The resulting mixture was stirred at 25 °C for 1 h during which a solid product formed. The suspension was filtered and the filter cake was washed with THF (300 mL × 3). The filtrate was concentrated under reduced pressure to give N(9-((2R,3R,4R,5R)-3-chloro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide (36 g, 92.3 mmol, 95% yield) as a white solid product; MS (ES) + ) C 17 H 16 ClN5O4 theoretical value: 389, measured value: 390 [M+H] + ;

[0298] Steps 5-7 [ka] The transformation depicted in the above scheme was carried out following the procedure previously described for the synthesis of intermediate C, steps 1-3.

[0299] (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4-chloro-2(hydroxymethyl)tetrahydrofuran-3-yl hydrogen phosphonate (Intermediate F): white solid (13.0 g, 27.8 mmol, 30% for 3 steps); 1 H NMR:(400MHz DMSO-d6)δ ppm 11.28(br s,1H),8.78(br d,J=4.0Hz,2H),8.05(br d,J=7.4Hz,2H),7.60-7.68(m,1H),7.55(br t,J=7.5Hz,2H),6.34(br d,J=5.9Hz,1H),5.27(br d,J=5.1Hz,1H),5.02(br s,1H),4.30(br s,1H),3.74(br s,2H),3.01-3.11(m,2H); 31 P NMR:(162MHz DMSO-d6)δ 0.63 ppm.

[0300] Example 1a and Example 1b Cyclic dinucleotides RR-CD-A-7dA and SR-CD-A-7dA Dithio-[R p ,R p ]-Cyclic-[A(2',5')p-7dA(3',5')p] Dithio-[S p ,R p ]-Cyclic-[A(2',5')p-7dA(3',5')p] [ka] Step 1 [ka] Compound 1-1 To a solution of intermediate B (4.00 g, 6.16 mmol) in CH3CN (50 mL) was added pyridine-TFA (2.38 g, 12.3 mmol, 2.0 eq), followed by a mixture of intermediate D (6.70 g, 6.78 mmol, 1.10 eq) and 3 Å molecular sieves (1.0 g, 24.6 mmol, 4.0 eq) in CH3CN (50 mL) and the resulting mixture was stirred at RT for 30 min. DDTT (1.52 g, 7.39 mmol, 1.20 eq) was added and the mixture was stirred at RT for another 30 min. The volatiles were removed under reduced pressure to give the crude product 1-1 (9.04 g), which was used in the next step without further purification.

[0301] Step 2 [ka] Compound 1-2 To a solution of ClCHCOOH in CHCl (6% v / v, 200 mL) was added HO (2.0 g, 111 mmol, 2.0 mL, 18.0 eq) and compound 1-1 from the previous step (9.04 g, estimated to be 6.16 mmol). The reaction mixture was stirred at RT for 0.5 h, then quenched with pyridine (120 mL) and concentrated under reduced pressure to give crude compound 1-2 (7.18 g), which was used in the next step without further purification. MS(ES + ) C 50 H 67 N 10 O 13 P2SSi2 theoretical value: 1165, measured value: 1165.3[M+H]+.

[0302] Step 3 [ka] Compound 1-3 To a solution of compound 1-2 from the previous step (estimated 7.18 g, 6.16 mmol) in pyridine (50 mL) was added DMOCP (3.98 g, 21.6 mmol, 3.5 eq). The mixture was stirred at RT for 0.5 h. To this mixture was then added the beaucaage reagent (3H-1,2-benzodithiol-3-one 1,1-dioxide, 1.85 g, 9.24 mmol, 1.5 eq) and the resulting mixture was stirred at RT for an additional 30 min. The reaction mixture was quenched by the addition of 3.4% aq. NaHCO3 (1.0 L) and then extracted with EtOAc (2 x 500 mL). The combined organic layers were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (CH2Cl2 / MeOH=30 / 1 to 15 / 1) to give compound 1-3 (3.0 g, 2.04 mmol) as a mixture of diastereoisomers, which was used directly in the next step.

[0303] Step 4 [ka] Compound 1-4 To a solution of compound 1-3 (3.0 g, 2.04 mmol) from the previous step in MeOH (30 mL) was added NH4OH (32.8 g, 935 mmol, 458 eq). The mixture was stirred at 50 °C for 12 h in a pressure-safe steel vessel and then concentrated under reduced pressure. The residue was purified by prep-HPLC (PHENOMENEX® LUNA® C18 250*50 10 um; mobile phase: A: H2O (10 mM NH4HCO3); B: MeCN; A%-B%=20%-50%, 20 min) to give two products: compound 1-4a (R p R p Or S p R p diastereoisomer; 380 mg, 0.391 mmol) and compound 1-4b (S p R p or R p R p diastereoisomer; 350 mg, 0.349 mmol) was obtained as a white solid.

[0304] Step 5 [ka] Compound 1-5 To a solution of compound 1-4a (200 mg, 218 umol) in MeOH (5.0 mL), NHF (80.7 mg, 2.18 mmol, 10.0 eq) was added and the resulting mixture was stirred at 60° C. for 16 h. After removing the volatiles under reduced pressure, the residue was purified by prep-HPLC [Waters Xbridge 150*25 5 um; mobile phase: A: H2O (10 mM NH4HCO3); B: MeCN; A%-B%=1%-20%, 10.5 min] to give compound 1-5a (30 mg, 40 umol) as a white solid.

[0305] Reaction of compound 1-4b in a similar manner gave compound 1-5b (30 mg, 40 umol) as a white solid.

[0306] Step 6 [ka] (1R,6R,8R,9R,10R,12R,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-8-(4-amino-7H-pyrrolo-[2,3-d]pyrimidin-7-yl)-9,18-dihydroxy-3,12-dimercapto-2,4,7,11,13,16-hexaoxa-3λ 5 ,12λ 5 -Diphosphatricyclo[13.2.1.0 6,10 ]Octadecane-3,12-dione (1-5), disodium salt (Examples 1a and 1b) A solution of compound 1-5a (30.0 mg, 41.5 umol) in HO (5.0 mL) was diluted with DOWEX®-50WX8 (Na + 300 mg) was added and the mixture was stirred at RT for 0.5 h. The reaction was then filtered and the filtrate was lyophilized to give Example 1a (R p ,R p Or S p ,R p The compound was obtained as a white solid (28.0 mg, 38.1 umol). MS(ES + ) C 21 H 26 N9O 10 P2S2 theoretical value: 690, measured value: 690.0 [M+H] + ; 1 H-NMR(400MHz,DMSO-d6)δ ppm 8.52(s,1H),8.26(s,1H),8.19(s,1H),7.50(d,J=3.6Hz 1H),6.85(d,J=3.6Hz,1H),6.09-6.13(m,2H),5.46(d,J=8.8Hz,1H),5.2 8-5.30(m,1H)4.63(d,J=4Hz,1H),4.03-4.27(m,5H),3.64-3.69(m,2H); 31 P NMR(162MHz,DMSO-d6)δ ppm 60.19,56.77; R t =1.797min [Waters XBridge Shield RP18 2.1*50mm, 5um;Mobile phase:A:H2O+10mM NH4HCO3;B:MeCN;A%-B%=0%-30%,5.2min]

[0307] Similarly, the compound 1-5b was reacted to give Example 1b (S p ,R p or R p ,R p The compound was obtained as a white solid (30.0 mg, 39.6 umol). MS(ES + ) C 21 H 26 N9O 10 P2S2 theoretical value: 690, measured value: 690.0 [M+H] + ; 1 H-NMR(400MHz,DMSO-d6)δ ppm 8.50(s,1H),8.29(s,1H),8.19(s,1H),7.62(d,J=3.2Hz 1H),6.85(d,J=4.0Hz,1H),6.09-6.14(m,2H),5.19-5.29(m,2H),4.68(dd,J=7.6Hz, 1H),4.37(d,J=4.0Hz,1H),4.11-4.20(m,3H),3.95-3.99(m,1H),3.69-3.81(m,2H); 31 P NMR(162MHz,CD3OD)δ ppm 59.29,51.96;R t =2.101min [Waters XBridge Shield RP18 2.1*50mm,5um;Mobile phase:A:H2O+10mM NH4HCO3;B:MeCN;A%-B%=0%-30%,5.2min].

[0308] Example 2a and Example 2b cyclic dinucleotides RR-CD-A-2'FA and SR-CD-A-2'FA; Dithio-[R p ,R p ]-cyclic-[A(2',5')p-2'FA(3',5')p] Dithio-[S p ,R p ]-cyclic-[A(2',5')p-2'FA(3',5')p] [ka] Step 1 [ka] Compound 2-1 To a solution of intermediate C (4.0 g, 9.15 mmol) in CH2Cl2 (40 mL) was added TEA (463 mg, 4.58 mmol, 0.50 eq). The mixture was stirred at RT for 5 min and the volatiles were removed under reduced pressure. The residue was dissolved in CH3CN (40.00 mL) and pyridine-TFA (3.53 g, 18.3 mmol, 2.0 eq) was added followed by a mixture of intermediate D (9.04 g, 9.15 mmol, 1.0 eq) and 3 Å molecular sieves (1.48 g, 36.6 mmol, 4.0 eq) in CH3CN (40 mL) and the resulting mixture was stirred at RT for 30 min. DDTT (2.25 g, 10.98 mmol, 1.2 eq) was added and the mixture was stirred at RT for another 30 min. The volatiles were removed under reduced pressure to give the crude product 2-1 (12.4 g), which was used in the next step without further purification.

[0309] Step 2 [ka] Compound 2-2 To a solution of ClCHCOOH in CHCl (6% v / v, 200 mL) was added compound 2-1 from the previous step (estimated 12.4 g, 9.15 mmol) and HO (2.00 g, 111 mmol, 2.0 mL, 12.1 eq). The reaction mixture was stirred at RT for 0.5 h, quenched with pyridine (100 mL), and concentrated under reduced pressure to give compound 2-2 (9.64 g), which was used in the next step without further purification.

[0310] Step 3 [ka] Compound 2-3 To a solution of compound 2-2 from the previous step (estimated 9.63 g, 9.15 mmol) in pyridine (200 mL), DMOCP (5.90 g, 32.0 mmol, 3.5 eq) was added and the mixture was stirred at RT for 0.5 h. Then, 3H-1,2-benzodithiol-3-one 1,1-dioxide (2.75 g, 13.7 mmol, 1.5 eq) was added and the resulting mixture was stirred at RT for another 30 min. The reaction mixture was quenched by the addition of 3.4% aq. NaHCO3 (1.0 L) and then extracted with EtOAc (2 x 500 mL). The combined organic layers were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and then concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (CH2Cl2 / MeOH=30 / 1 to 10 / 1) to give compound 2-3 (3.2 g, 2.1 mmol) as a mixture of diastereoisomers, which was used directly in the next step.

[0311] Step 4 [ka] Compound 2-4 To a solution of compound 2-3 (2.0 g, 1.87 mmol) from the previous step in MeOH (10 mL) was added NH4OH (18.2 g, 519 mmol, 277 eq). The mixture was stirred at 50 °C for 16 h in a pressure-safe steel vessel and then concentrated under reduced pressure. The residue was purified by prep-HPLC (PHENOMENEX® LUNA® C18 250*50 10 um; mobile phase: A: H2O (10 mM NH4HCO3); B: MeCN; A%-B%=10%-40%, 20 min] to give two products: compound 2-4a (R p R p Or S p R p diastereoisomer; 180 mg, 0.209 mmol) and compound 2-4b (S p R p or R p R p diastereoisomer; 200 mg, 0.228 mmol) was obtained as a white solid.

[0312] Step 5 [ka] Compound 2-5 To a solution of compound 2-4a (100 mg, 119 umol) in MeOH (3.0 mL), NHF (44.1 mg, 1.19 mmol, 10 eq) was added and the resulting mixture was stirred at 60° C. for 16 h. The reaction mixture was then allowed to cool to RT and then concentrated under reduced pressure. The residue was dissolved in HO (0.5 mL), cooled to 10° C., and maintained under stirring for 30 min, then filtered and the filter cake was collected to give compound 2-5a (30.0 mg, 41.3 umol) as a white solid. MS(ES + ) C 20 H 24 FN 10 O9P2S2 Theoretical value: 693, Measured value: 693.2 [M+H] + ; 1 H-NMR(400MHz,CD3OD)δ ppm 8.98(s,1H),8.22(s,2H),7.82(s,1H),6.45(d,J=14.4Hz,1H),6.33(d,J=8.0Hz,1H),5.62(d,J=53.8 Hz,1H),5.32(m,1H),5.07-5.13(m,1H),4.36-4.46(m,5H),4.06(d,J=11.2Hz,1H),3.86-3.90(m,1H).

[0313] Compound 2-5b (30.0 mg, 41.3 umol) was obtained as a white solid by the reaction of compound 2-4b in a similar manner. MS(ES + ) C 20 H 24 FN 10 O9P2S2 Theoretical value: 693, Measured value: 693.2 [M+H] + ; 1H-NMR(400MHz,CD3OD)δ ppm 8.76(s,1H),8.49(s,1H),8.24(s,1H),8.18(s,1H),6.34-6.41(m,2H),5.70(dd,J= 51.8Hz,1H),5.22-5.239(m,2H),4.50-4.59(m,4H),4.32(s,1H),4.03-4.07(m,1H).

[0314] Step 6 [ka] (1R,6R,8R,9R,10R,12R,15R,17R,18R)-8,17-di(6-amino-9H-purin-9-yl)-9-fluoro-18-hydroxy-3,12-dimercapto-2,4,7,11,13,16-hexaoxa-3λ 5 ,12λ 5 -Diphosphatricyclo-[13.2.1.0 6,10 ]Octadecane-3,12-dione (2-5), disodium salt (Examples 2a and 2b) To a solution of compound 2-5a (30.0 mg, 41.3 umol) in HO (10.0 mL) was added Dowex®-50WX8 (Na + 300 mg) was added and the mixture was stirred at RT for 4 h. The reaction was then filtered and the filtrate was lyophilized to give Example 2a (R p R p Or S p R p ; 30.0 mg, 40.6 umol) was obtained as a white solid. MS(ES + ) C 20 H 24 FN 10 O9P2S2 Theoretical value: 693, Measured value: 693.0 [M+H] + ; 1H-NMR(400MHz,DMSO-d6)δ ppm 8.56(s,1H),8.40(s,1H),8.17(s,1H),8.13(s,1H),7.34(s,2H),7.22(s,2H),6.23(m,1H),6.09(d,J=8.4Hz 1H),5.71(d,J=52.8Hz,1H),5.54(s,1H),5.15-5.30(m,2H),3.91-4.37(m,5H),3.67-3.70(m,1H); 31 P NMR(162MHz,CD3OD)δ ppm 55.97,53.66;R t =1.384 points [Waters XBridge Shield RP18 2.1*50mm, 5um; mobile phase: A: H2O+10mM NH4HCO3; B: MeCN; A%-B%=0%-30%, 5.2 points].

[0315] The same as the compound 2-5b and the reverse compound 2-5b, Example 2b (S p R p Also p R p , 28.0mg, 40.6umol) is a white solid. MS(ES + )C 20 H 24 FN 10 O9P2S2 theoretical value: 693, measured value: 693.0 [M+H] + ; 1 H-NMR(400MHz,CD3OD)δ ppm 8.86(br s,1H),8.39(s,1H),8.19(s,1H),8.02(br s,1H),6.35-6.41(m,2H),5.70(d,J=51.8Hz,1H),5.22-5.27(m,2H),4.35-4.60(m,5H),4.05-4.08(m,2H); 31 P NMR(162MHz,CD3OD)δ ppm 57.39,52.28;R t =1.644 points [Waters XBridge Shield RP18 2.1*50mm, 5um; mobile phase: A: H2O+10mM NH4HCO3; B: MeCN; A%-B%=0%-30%, 5.2 points].

[0316] Example 3a and Example 3b Cyclic dinucleotides RR-CD-7dA-A and SR-CD-7dA-A Dithio-[R p ,R p ]-cyclic-[7dA(2',5')pA(3',5')p] Dithio-[S p ,R p ]-cyclic-[7dA(2',5')pA(3',5')p] [ka] Step 1 [ka] Compound 3-1 To a solution of intermediate E (3.0 g, 4.61 mmol) in CH3CN (30 mL) was added pyridine-TFA (1.78 g, 9.22 mmol, 2.0 eq), followed by a mixture of intermediate A (5.0 g, 5.07 mmol, 1.1 eq) and molecular sieves (0.8 g, 18.4 mmol, 4.00 eq) in CH3CN (30 mL) and the resulting mixture was stirred at RT for 30 min. DDTT (1.14 g, 5.53 mmol, 1.2 eq) was added and the mixture was stirred at RT for another 30 min. The volatiles were removed under reduced pressure to give crude compound 3-1 (6.77 g), which was used in the next step without further purification.

[0317] Step 2 [ka] Compound 3-2 To a solution of ClCHCOOH acid in CHCl (6% v / v, 100 mL) was added HO (83.1 mg, 4.61 mmol, 83.12 uL, 1.00 eq) and compound 3-1 from the previous step (6.77 g, estimated to be 4.61 mmol). The reaction mixture was stirred at RT for 0.5 h, then quenched with pyridine (80 mL) and concentrated under reduced pressure to give compound 3-2 (5.48 g), which was used in the next step without further purification.

[0318] Step 3 [ka] Compound 3-3 To a solution of compound 3-2 from the previous step (estimated 5.48 g, 4.61 mmol) in pyridine (150 mL), DMOCP (4.77 g, 25.8 mmol, 5.5 eq) was added and the mixture was stirred at RT for 0.5 h. Then, 3H-1,2-benzodithiol-3-one 1,1-dioxide (1.41 g, 7.05 mmol, 1.5 eq) was added and the resulting mixture was stirred at RT for another 30 min. The reaction mixture was quenched by the addition of 3.4% aq. NaHCO3 (600 mL) and then extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and then concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (CH2Cl2 / MeOH=30 / 1 to 15 / 1) to give compound 3-3 (3.0 g, 1.53 mmol) as a mixture of diastereoisomers, which was used directly in the next step.

[0319] Step 4 [ka] Compound 3-4 To a solution of compound 3-3 (3.0 g, 1.53 mmol) from the previous step in MeOH (30 mL) was added NH4OH (16.4 g, 468 mmol, 307 eq). The mixture was stirred at 50 °C for 16 h in a pressure-safe steel vessel and then concentrated under reduced pressure. The residue was purified by prep-HPLC [PHENOMENEX® LUNA® C18 250*50 10 um; mobile phase: A: H2O (10 mM NH4HCO3); B: MeCN; A%-B%=20%-45%, 20 min] to give compound 3-4a (R p R p Or S p R p diastereoisomers, 220 mg, 208 umol) and compound 3-4b (S p R p or Rp R p diastereoisomer, 220 mg, 208 mmol) was obtained as a white solid.

[0320] Step 5 [ka] Compound 3-5 To a solution of compound 3-4a (100 mg, 105 umol) in MeOH (3.0 mL), NHF (38.9 mg, 1.05 mmol, 10 eq) was added and the resulting mixture was stirred at 60° C. for 12 h. The reaction mixture was then allowed to reach RT and concentrated under reduced pressure. The residue was dissolved in HO (1 mL) at 40° C., cooled to 5° C., and then maintained under stirring for 30 min before being filtered and the filter cake was collected to give compound 3-5a (20.0 mg, 26.3 umol) as a white solid.

[0321] Compound 3-5b (33.0 mg, 45.6 umol) was obtained as a white solid by the reaction of compound 3-4b in a similar manner.

[0322] Step 6 [ka] (1R,6R,8R,9R,10R,12R,15R,17R,18R)-17-(4-amino-7H-pyrrolo-[2,3-d]pyrimidin-7-yl)-8-(6-amino-9H-purin-9-yl)-9,18-dihydroxy-3,12-dimercapto-2,4,7,11,13,16-hexaoxa-3λ 5 ,12λ 5 -Diphosphatricyclo[13.2.1.0 6,10 ]Octadecane-3,12-dione, disodium salt (Examples 3a and 3b) A solution of compound 3-5a (20.0 mg, 27.6 umol) in HO (5 mL) was diluted with DOWEX® 50WX8 (Na +Form; 300 mg) was added and the mixture was stirred at RT for 3 h. The reaction was then filtered and the filtrate was lyophilized to give Example 3a as a white solid (R p R p Or S p R p , 18.0 mg, 24.5 umol). MS(ES + ) C 21 H 26 N9O 10 P2S2 theoretical value: 690, measured value: 690.0 [M+H] + ; 1 H-NMR(400MHz,CD3OD)δ ppm 8.33(s,1H),8.20(s,1H),8.05(s,1H),7.84(d,J=4.0Hz 1H),6.62(d,J=3.6Hz,1H),6.51(d,J=8.4Hz,1H),6.12(d,J=6.8Hz,1H),5.59-5.60(m,1H),5.3 5-5.59(m,1H),5.21-5.24(m,1H),4.25-4.45(m,4H),3.99(d,J=12.0Hz,1H),3.90-3.92(m,1H); 31 P NMR(162MHz,CD3OD)δ ppm 60.36,60.28;R t =1.497min [Waters XBridge Shield RP18 2.1*50mm,5um;Mobile phase:A:H2O+10mM NH4HCO3;B:MeCN;A%-B%=0%-30%,5.2min].

[0323] Similarly, the compound 3-5b was reacted to give Example 3b (S p R p or R p R p , 33.0 mg, 44.9 umol) was obtained as a white solid. MS(ES + ) C 21 H 26 N9O 10 P2S2 theoretical value: 690, measured value: 690.0 [M+H] + ; 1H-NMR(400MHz,CD3OD)δ ppm 8.34(s,1H),8.21(s,1H),8.07(s,1H),7.97(d,J=3.6Hz 1H),6.72(d,J=4Hz,1H),6.56(d,J=8.0Hz,1H),6.12(d,J=3.2Hz,1H),5.20-5.31(m,2H),4.9 8-5.01(m,1H),4.71(d,J=4Hz,1H),4.33-4.49(m,1H),4.25-4.30(m,3H),4.07-4.12(m,1H); 31 P NMR(162MHz,CD3OD)δ ppm 57.30,53.90;R t =1.647min [Waters XBridge Shield RP18 2.1*50mm,5um;Mobile phase:A:H2O+10mM NH4HCO3;B:MeCN;A%-B%=0%-30%,5.2min].

[0324] Examples 4a, 4b, 4c and 4b Cyclic dinucleotides RR-CD-A-2'Cl-A, RS-CD-A-2'Cl-A, SS-CD-A-2'Cl-A, and SR-CD-A-2'Cl-A Dithio-[R p ,R p ]-cyclic-[A(2',5')p-2'Cl-A(3',5')p], dithio-[R p ,S p ]-cyclic-[A(2',5')p-2'Cl-A(3',5')p], dithio-[S p ,S p ]-cyclic [A(2',5')p-2'Cl-A(3',5')p] Dithio-[S p ,R p ]-cyclic-[A(2',5')p-2'Cl-A(3',5')p] [ka] Step 1 [ka] Compound 4-1 To a solution of Int F (3.00 g, 6.61 mmol, 1.0 eq) in DCM (60 mL) was added TEA (0.334 g, 3.31 mmol, 0.46 uL, 0.5 eq). Volatiles were removed under reduced pressure and pyridine-TFA (2.55 g, 13.2 mmol, 2.0 eq) was added to the residue, after which the mixture was co-evaporated three times with anhydrous CH3CN (40 mL). The residue was dissolved in anhydrous CH3CN (30 mL) and stirred with 3 Å molecular sieves (3.00 g, 6.61 mmol, 1.0 eq) for 5 min. In a separate vessel, Int D (6.53 g, 6.61 mmol, 1.0 eq) was co-evaporated three times with anhydrous CH3CN (20 mL) and then dissolved in anhydrous CH3CN (30 mL). To the resulting solution of Int D was added a mixture of Int F, pyridine-TFA and 3 Å molecular sieves followed by DDTT (1.63 g, 7.93 mmol, 1.2 eq) and the resulting mixture was stirred for 30 min at 25° C. The mixture was then concentrated under reduced pressure to give compound 4-1 (9.0 g) as a yellow solid, which was used in the next step without further purification.

[0325] Step 2 [ka] Compound 4-2 To a solution of compound 4-1 (9.0 g, 6.56 mmol, 1.0 eq) in DCM (90 mL) was added Cl2CHCOOH acid (2.7 mL). The mixture was stirred at 25 °C for 1 h, then triethylsilane (4.57 g, 39.3 mmol, 6.28 mL, 6.0 eq) was added, followed by pyridine (45.0 mL). The resulting mixture was stirred at RT for 30 min, then concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (DCM:MeOH = 10:1 to 3:1) to give compound 4-2 (2.12 g, 1.98 mmol, 30% yield) as a pale yellow solid. MS (ES) + ) C 43 H 50 ClN 11 O 12 P2SSi Theoretical value: 1069, Measured value: 1070 [M+H] + .

[0326] Step 3 [ka] Compound 4-3a and Compound 4-3b Compound 4-2 (2.12 g, 1.98 mmol, 1.0 eq) was coevaporated three times with anhydrous pyridine (40.0 mL) and dissolved in anhydrous pyridine (40.0 mL), and the solution was cooled to 0° C. DMOCP (1.28 g, 6.93 mmol, 3.5 eq) was added and the mixture was stirred at RT for 0.5 h. Then, 3H-1,2-benzodithiol-3-one 1,1-dioxide (0.595 g, 2.97 mmol, 1.5 eq) was added and the resulting mixture was stirred at RT for another 30 min. The reaction mixture was quenched by the addition of 3.4% aq. NaHCO3 (600 mL) and then extracted with EtOAc (2×300 mL). The combined organic layers were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by SiO2 gel chromatography (CH2Cl2 / MeOH = 30 / 1 to 10 / 1) to give compound 4-3a (0.470 g, 0.348 mmol, 17% yield) and compound 4-3b (0.380 g, 0.28 mmol, 14% yield), each as a mixture of diastereoisomers with unclear stereochemistry at the phosphorothioate center.

[0327] Step 4 [ka] Compounds 4-4a, 4-4b, 4-4c, 4-4d To a solution of compound 4-3a (0.47 g, 0.43 mmol, 1.0 eq) in MeOH (3 mL) was added NH4OH (4.2 g, 519 mmol, 277 eq). The mixture was stirred at 50° C. for 16 h in a pressure-safe steel vessel, then cooled to RT and concentrated under reduced pressure. The residue was purified by prep-HPLC [Agela Durashell® C18 150×25 5 um; mobile phase: A: H2O (10 mM NH4HCO3); B: MeCN; A%-B%=10%-40%, 10.5 min] to give two stereoisomeric products with unclear stereochemistry at the phosphorothioate center; compound 4-4a (93.0 mg, 0.11 mmol, 25% yield) and compound 4-4c (105 mg, 0.13 mmol, 29% yield), both as white solids.

[0328] Compound 4-3b (0.380 g, 0.28 mmol) was reacted in a similar manner to give two stereoisomeric products with uncertain stereochemistry at the holothioate center, compound 4-4b (82.0 mg, 99.6 umol, 28% yield) and compound 4-4d (82.0 mg, 99.6 umol, 28% yield), both as white solids.

[0329] Step 5 [ka] Compounds 4-5a, 4-5b, 4-5c, 4-5d To a solution of compound 4-4a (93.0 mg, 0.11 mmol, 1.0 eq) in MeOH (3.0 mL) was added NHF (80 mg, 2.17 mmol, 20 eq) and the resulting mixture was stirred for 16 h at 65° C. The reaction mixture was then allowed to cool to RT and then concentrated under reduced pressure. The residue was purified by prep-HPLC [Agela Durashell® C18 150×25 5um; mobile phase: A: HO (10 mM NH4HCO3); B: MeCN; A%-B%=10%-40%, 10.5 min] to give compound 4-5a (50.0 mg, 65.1 umol, 60%) as a white solid; compounds 4-4b, 4-4c and 4-4d were reacted in the same manner to give the following compounds: 4-5b (40.0 mg, 56.4 umol, 56% yield); 4-5c (58.0 mg, 78.1 umol, 64% yield); and 4-5d (20.0 mg, 22.6 umol, 23% yield).

[0330] Step 6 [ka] Examples 4a, 4b, 4c and 4d A solution of compound 4-5a (50.0 mg, 67.3 umol, 1.0 eq) in HO (20.0 mL) was diluted with Dowex®-50WX8 (Na + (500 mg) was added and the mixture was stirred at RT for 4 h. The reaction was then filtered and the filtrate was lyophilized to give Example 4a (36.5 mg, 46.6 umol, 69% yield) as a white solid; single stereoisomer, uncertain stereochemistry at the phosphorothioate center; MS (ES + ) C 20 H 23 ClN 10 O9P2S2 Theoretical value: 708, Measured value: 709 [M+H] + ; 1H-NMR(400MHz D2O)δ ppm 8.68(s,1H),8.13(s,1H),8.07(s,1H),8.01(s,1H),6.28(d,J=2.0Hz,1H),6.17(d, J=8.4Hz,1H),5.29-5.40(m,2H),5.18-5.26(m,1H),4.62(d,J=4.0Hz,1H),4.57(br s,1H),4.42-4.51(m,2H),4.14-4.25(m,2H),4.09(br d,J=12.8Hz,1H); 31 P NMR(162MHz,D2O)δ ppm 55.69,54.83;R t =1.64min [Waters XBridge Shield RP18 2.1*50mm,5um;Mobile phase:A:H2O+10mM NH4HCO3;B:MeCN;A%-B%=0%-30%,5.2min].

[0331] Compounds 4-5b, 4-5c and 4-5d were reacted similarly to give the following compounds, all single stereoisomers with uncertain stereochemistry at the holothioate center.

[0332] Example 4b (40.0 mg, 48.2 umol, 89.6% yield); MS (ES + ) C 20 H 23 ClN 10 O9P2S2 Theoretical value: 708, Measured value: 709 [M+H] + ; 1 H-NMR(400MHz D2O)δ ppm 8.42(s,1H),8.16(s,1H),8.04(s,1H),7.94(s,1H),6.26(d,J=3.1Hz,1H),6.20(d,J=8.3Hz,1H),5.33-5. 43(m,2H),5.09-5.13(m,1H),4.55-4.61(m,2H),4.42-4.49(m,3H),4.34-4.41(m,1H),4.05-4.14(m,2H); 31 P NMR(162MHz,D2O)δ ppm 56.58,54.75;R t=1.74 points [Waters XBridge Shield RP18 2.1*50mm, 5um; mobile phase: A: H2O+10mM NH4HCO3; B: MeCN; A%-B%=0%-30%, 5.2 points].

[0333] Example 4c (35.2 mg, 46.6 umol, 59.7% yield); MS (ES + )C 20 H 23 C1N 10 O9P2S2 theoretical value: 708, experimental value: 709 [M+H] + ; 1 H-NMR(400MHz D2O)δ ppm 8.65(s,1H),8.19(s,1H),8.08(s,1H),8.05(s,1H),6.37(s,1H),6.17(d,J=8.3Hz,1H) ,5.42(d,J=4.8Hz,1H),5.33(m,1H),5.08-5.16(m,1H),4.93(d,J=3.9Hz,1H),4.62(br d,J=9.0Hz,1H),4.44-4.51(m,2H),4.27(m,1H),4.18(br s,2H); 31 P NMR(162MHz,D2O)δ ppm 53.99,51.92;R t =2.09 points [Waters XBridge Shield RP18 2.1*50mm, 5um; mobile phase: A: H2O+10mM NH4HCO3; B: MeCN; A%-B%=0%-30%, 5.2 points].

[0334] Example 4d (17.0 mg, 24.0 umol, 89.1% yield); MS (ES + )C 20 H 23 C1N 10 O9P2S2 theoretical value: 708, experimental value: 709 [M+H] + ; 1H-NMR(400MHz D2O)δ ppm 8.34(s,1H),8.10(s,1H),8.04(s,1H),7.86(s,1H),6.30(s,1H),6.14(d,J=8.4Hz, 1H),5.36(m,1H),5.24(m,1H),5.05(d,J=4.4Hz,1H),4.80(d,J=4.0Hz,1H),4.55(br d,J=8.0Hz,1H),4.36-4.44(m,2H),4.32(ddd,J=12.0,6.4,2.0Hz,1H),4.20(m,1H),4.02(dd,J=11.2,3.6Hz,1H); 31 P NMR(162MHz,D2O)δ ppm 54.64,52.01;R t =2.03min [Waters XBridge Shield RP18 2.1*50mm,5um;Mobile phase:A:H2O+10mM NH4HCO3;B:MeCN;A%-B%=0%-30%,5.2min].

[0335] The following compounds, or their salts, esters, prodrugs, or tautomers, can generally be made using the methods described above. It is expected that these compounds, once made, will have similar activity as they are prepared. [ka]

[0336] Bioactivity assays THP-1 dual assay The INVIVOGEN® THP-1 Dual™ assay (catalog code: thpd-nfis) was used to evaluate the listed compounds as agonists of the STING receptor. THP-1 Dual™ cells are derived from the human monocytic cell line THP-1 by stable integration of two inducible reporter constructs. This assay allows the simultaneous study of two major signaling pathways for STING: (a) the NF-κB pathway by monitoring the activity of secreted embryonic alkaline phosphatase (SEAP); and (b) the interferon regulatory factor (IRF) pathway by evaluating the activity of secreted luciferase (Lucia™).

[0337] The procedure described by the manufacturer was followed with the following modifications: (1) plates were incubated for 18 hours after addition of the cell suspension, and (2) no optional differentiation step was used.

[0338] Tables 1 and 2. Biological activity [Table 1]

[0339] [Table 2]

[0340] Mouse pancreatic ductal carcinoma assay Using mouse organoids, we followed the procedure of Boj et al. (Cell 2015, 160, 324-338). 5 MT4-2D cells were injected subcutaneously into the right flank of male 6-week-old C57BL / 6J mice. On day 15, 5ug of the indicated STING agonist was injected intratumorally in a volume of 50ul.

[0341] [Table 3]

[0342] All references, patents, or patent applications (U.S. or foreign) cited in this application are hereby incorporated by reference as if set forth in their entirety herein. In the event of any conflict, the material literally disclosed herein will control.

[0343] From the foregoing description, those skilled in the art can easily ascertain the essential features of the present invention, and can make various changes and modifications to the present invention to adapt it to various usages and conditions without departing from the spirit and scope thereof.

Claims

1. A compound of structural formula (I) or a salt or tautomer thereof: 【Chemistry 1】 (In the formula, A 1 is CH and A 2 is N or A 1 is N and A 2 is CH or A 1 is CH and A 2 is CH; R 1a and R 1b is H and NH 2 are independently selected from; R 2 is OH, F, Cl, N 3 , and N.H. 2 Selected from: R 3 is OH, F, Cl, N 3 , and N.H. 2 Selected from: R 4a and R 4b NH 2 and N.H.R. 5 are independently selected from; R 5 is independently selected from methyl, ethyl, and propyl; However, here, A 1 When is CH, R 4a is NHR 5 Instead of: A 2 When is CH, R 4b is NHR 5 isn't it.)

2. A 1 is CH, and A 2 The compound according to claim 1, wherein

3. A 1 is N, and A 2 The compound of claim 1, wherein is CH.

4. A 1 is CH, and A 2 The compound of claim 1, wherein is CH.

5. R 2 The compound of claim 1, wherein is selected from F and Cl.

6. 2. The compound of claim 1, wherein the compound has the structural formula (II) or a salt or tautomer thereof. 【Chemistry 2】 (In the formula, A 1 is CH and A 2 is N or A 1 is N and A 2 is CH or A 1 is CH and A 2 is CH; R 1a and R 1b is H and NH 2 are independently selected from; R 2 is selected from OH, F, and Cl; R 3 is OH; R 4a and R 4b NH 2 It is.)

7. A 1 is CH, and A 2 The compound according to claim 6, wherein

8. A 1 is N, and A 2 The compound of claim 6, wherein is CH.

9. A 1 is CH, and A 2 The compound of claim 6, wherein is CH.

10. R 2 The compound according to claim 6, wherein is selected from F and Cl.

11. 2. The compound according to claim 1, wherein the compound is the following compound or a salt or tautomer thereof: 【Chemistry 3】

12. 2. The compound according to claim 1, wherein the compound is the following compound or a salt or tautomer thereof: 【Chemistry 4】

13. 2. The compound of claim 1, wherein the compound is selected from the following compounds, or any salt or tautomer thereof: 【Chemistry 5】

14. 2. The compound according to claim 1, wherein the compound is the following compound or a salt or tautomer thereof: 【Chemistry 6】

15. 13. A pharmaceutical composition comprising a compound according to claim 1 for use as a medicament.

16. 13. A pharmaceutical composition comprising a compound according to claim 1 for use in the treatment of cancer.

17. A pharmaceutical composition for the prevention or treatment of a disease or condition ameliorated by receptor activation of STING, comprising a compound described in claim 1, wherein the disease or condition is selected from the group consisting of an autoimmune disease or disorder, an immune deficiency or deficiency, an inflammatory disease or disorder, and cancer.

18. 11. A drug delivery vehicle comprising a compound of claim 1 conjugated to a targeting moiety, said targeting moiety being covalently attached to the compound of claim 1, said targeting moiety being selected from the group consisting of a peptide, biotin or a biotin analogue, a protein, transferrin and an antibody.

19. The drug delivery vehicle of claim 18 , wherein the targeting moiety is a peptide.

20. 20. The drug delivery vehicle of claim 18, wherein the targeting moiety is biotin or a biotin analogue.

21. The drug delivery vehicle of claim 18 , wherein the targeting moiety is a protein.

22. 20. The drug delivery vehicle of claim 18, wherein the targeting moiety is transferrin.

23. The drug delivery vehicle of claim 18 , wherein the targeting moiety is an antibody.

24. 24. The drug delivery vehicle of claim 23, wherein the targeting moiety is a monoclonal antibody.

25. A drug delivery vehicle comprising a compound of claim 1 contained within a container portion selected from a nanoparticle, a liposome, a micelle and a vesicle, the container portion partially or completely containing the compound of claim 1.

26. 26. The drug delivery vehicle of claim 25, wherein the container portion is a nanoparticle.

27. The drug delivery vehicle of claim 25 , wherein the container portion is a liposome.

28. The drug delivery vehicle of claim 25 , wherein the container portion is a micelle.

29. 26. The drug delivery vehicle of claim 25, wherein the container portion is a vesicle.

30. The drug delivery vehicle of any one of claims 25 to 29, wherein the container portion comprises a phospholipid.

31. further comprising a selectivity moiety, said selectivity moiety being providing selective delivery of said drug delivery vehicle to specific regions of the subject's body; providing selective delivery of said drug delivery vehicle to a specific site of an organ in the subject's body; providing selective delivery of said drug delivery vehicle to tumors; improve transport across biological membranes, Improves transport from the digestive tract to the bloodstream or The drug delivery vehicle of any one of claims 18 to 30, which improves transport across the blood-brain barrier.

32. 32. The drug delivery vehicle of claim 31, wherein the selectivity moiety enables selective delivery of the drug delivery vehicle to a particular organ of a subject's body.

33. 32. The drug delivery vehicle of claim 31, wherein the selectivity moiety enables selective delivery of the drug delivery vehicle to a tumor.

34. 13. A pharmaceutical composition comprising a compound of claim 1 in association with a pharma- ceutically acceptable carrier.

35. 20. A pharmaceutical composition comprising the drug delivery vehicle of claim 18 together with a pharma- ceutically acceptable carrier.

36. 26. A pharmaceutical composition comprising the drug delivery vehicle of claim 25 together with a pharma- ceutically acceptable carrier.

37. A pharmaceutical composition for treating a STING-mediated disease comprising a therapeutically effective amount of a compound described in claim 1, wherein the disease is selected from the group consisting of an autoimmune disease or disorder, an immune deficiency or defect, an inflammatory disease or disorder, and cancer.

38. A pharmaceutical composition for treating a STING-mediated disease, comprising a therapeutically effective amount of a drug delivery vehicle described in claim 18, wherein the disease is selected from the group consisting of an autoimmune disease or disorder, an immune deficiency or defect, an inflammatory disease or disorder, and cancer.

39. A pharmaceutical composition for treating a STING-mediated disease comprising a therapeutically effective amount of a drug delivery vehicle described in claim 25, wherein the disease is selected from the group consisting of an autoimmune disease or disorder, an immune deficiency or defect, an inflammatory disease or disorder, and cancer.

40. The pharmaceutical composition according to any one of claims 37 to 39, wherein the disease is cancer.

41. The pharmaceutical composition of claim 40, wherein the cancer is a chemotherapy-resistant cancer.

42. The pharmaceutical composition of claim 40, wherein the cancer is a radiotherapy-resistant cancer.

43. 41. The pharmaceutical composition of claim 40, wherein the cancer is selected from melanoma, cervical cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, urothelial cancer, bladder cancer, non-small cell lung cancer, small cell lung cancer, sarcoma, colorectal adenocarcinoma, one or more gastrointestinal stromal tumors, gastroesophageal cancer, colorectal cancer, pancreatic cancer, renal cancer, hepatocellular carcinoma, malignant mesothelioma, leukemia, lymphoma, myelodysplastic syndrome, multiple melanoma, transitional cell carcinoma, neuroblastoma, and one or more plasma cell neoplasms.

44. 41. The pharmaceutical composition of claim 40, wherein the cancer is melanoma.

45. The pharmaceutical composition of claim 40, wherein the cancer is metastatic.

46. The pharmaceutical composition of claim 40, wherein the cancer is lymphoma.

47. The pharmaceutical composition according to any one of claims 37 to 39, wherein the disease is an autoimmune disease or disorder.

48. The pharmaceutical composition according to any one of claims 37 to 39, wherein the disease is immunodeficiency or immunodeficiency.

49. The pharmaceutical composition according to any one of claims 37 to 39, wherein the disease is an allergic disease.

50. 50. The pharmaceutical composition of claim 49, wherein the allergic disease is selected from allergic rhinitis and asthma.

51. The pharmaceutical composition according to any one of claims 37 to 39, wherein the disease is an infectious disease.

52. 52. The pharmaceutical composition of claim 51, wherein the infectious disease is caused by a bacterial infection.

53. 52. The pharmaceutical composition of claim 51, wherein the infectious disease is caused by a viral infection.

54. below: a. a pharmaceutical composition according to any one of claims 37 to 39, and b. A pharmaceutical composition for the treatment of a STING-mediated disease comprising another therapeutic agent, The pharmaceutical composition, wherein said disease is selected from the group consisting of an autoimmune disease or disorder, an immune deficiency or defect, an inflammatory disease or disorder, and cancer.

55. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 for achieving an effect selected from induction of transcription of host defense genes, production of cytokines, release of chemokines, and priming of antigen-specific T cells.

56. 56. The pharmaceutical composition of claim 55, wherein the effect is the production of type I interferon.

57. 57. The pharmaceutical composition of claim 56, wherein the type I interferon is interferon alpha.

58. 57. The pharmaceutical composition of claim 56, wherein the type I interferon is interferon beta.

59. 13. A pharmaceutical composition comprising a sufficient amount of a compound according to claim 1 to induce STING-dependent type I interferon production in an individual.

Citation Information

Patent Citations

  • Cyclic purine dinucleotides as regulators of sting

    JP2018516903A

  • Compositions and methods for activating "interferon gene stimulator" dependent signaling

    JP2018534295A

  • Cyclic dinucleotide compounds and methods of use

    JP2019509339A

  • Cyclic dinucleotide STING agonists for the treatment of cancer

    JP2020503303A

  • Cyclic dinucleotides as agonists of interferon gene stimulator-dependent signal transduction

    JP2023022165A